Razelle Kurzrock
#67,423
Most Influential Person Now
Researcher
Razelle Kurzrock's AcademicInfluence.com Rankings
Razelle Kurzrockengineering Degrees
Engineering
#1247
World Rank
#1881
Historical Rank
Biomedical Engineering
#17
World Rank
#17
Historical Rank
Applied Physics
#90
World Rank
#94
Historical Rank
Razelle Kurzrockbiology Degrees
Biology
#2423
World Rank
#3842
Historical Rank
Molecular Biology
#142
World Rank
#146
Historical Rank
Biochemistry
#199
World Rank
#252
Historical Rank
Download Badge
Engineering Biology
Razelle Kurzrock's Degrees
- PhD Biomedical Engineering Stanford University
Why Is Razelle Kurzrock Influential?
(Suggest an Edit or Addition)Razelle Kurzrock's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy (2015) (1565)
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers (2017) (1504)
- The biology of chronic myeloid leukemia. (1999) (1293)
- Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer (2008) (1144)
- The molecular genetics of Philadelphia chromosome-positive leukemias. (1988) (854)
- Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial (2012) (835)
- Autophagy as a target for anticancer therapy (2011) (727)
- Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors. (2018) (657)
- Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate (2017) (631)
- Clinical toxicity of interferons in cancer patients: a review. (1986) (595)
- Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. (2012) (515)
- Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. (2012) (486)
- Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative (2012) (474)
- Chronic myelogenous leukemia: a concise update. (1993) (459)
- The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing (2015) (445)
- Liposome‐encapsulated curcumin (2005) (444)
- PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. (2012) (430)
- Epstein-Barr Virus and Cancer (2004) (418)
- Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. (2011) (412)
- Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. (1991) (402)
- Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. (2015) (396)
- Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. (2010) (390)
- Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells (2008) (387)
- Philadelphia ChromosomePositive Leukemias: From Basic Mechanisms to Molecular Therapeutics (2003) (363)
- Sweet's syndrome revisited: a review of disease concepts (2003) (357)
- PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors (2011) (338)
- Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. (2015) (334)
- Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study (2019) (333)
- International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. (2017) (320)
- Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer (2007) (320)
- PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas (2017) (313)
- Malignancy-associated Sweet's syndrome: review of the world literature. (1988) (309)
- Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. (1998) (307)
- ATM Mutations in Cancer: Therapeutic Implications (2016) (304)
- AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer (2015) (303)
- Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. (2018) (297)
- Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial (2019) (294)
- Novel patterns of response under immunotherapy (2019) (285)
- A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia (1987) (279)
- Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. (2001) (279)
- Interleukin‐6 and its receptor in cancer (2007) (276)
- Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis (2005) (276)
- HER2 expression status in diverse cancers: review of results from 37,992 patients (2015) (269)
- The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. (2020) (266)
- PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. (2013) (265)
- The biology of Hepatocellular carcinoma: implications for genomic and immune therapies (2017) (254)
- Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. (2019) (253)
- Nuclear factor‐κB and IκB kinase are constitutively active in human pancreatic cells, and their down‐regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis (2004) (253)
- Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. (2009) (241)
- The role of cytokines in cancer‐related fatigue (2001) (241)
- Vascular Endothelial Growth Factor and Its Relationship to Inflammatory Mediators (2007) (240)
- Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis. (2016) (239)
- Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall‐cell lung cancer, or pancreatic cancer (2009) (236)
- Cytokines in pancreatic carcinoma (2004) (234)
- Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions. (2013) (227)
- Sarcoidosis and malignancy. (2007) (226)
- A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. (1988) (226)
- Curcumin‐induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IκB kinase and nuclear factor κB activity and are independent of the B‐Raf/mitogen‐activated/extracellular signal‐regulated protein kinase pathway and the Akt pathway (2005) (222)
- Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. (2003) (221)
- Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. (2012) (218)
- Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. (2014) (216)
- Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics. (2018) (208)
- Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. (1993) (206)
- RAS and leukemia: from basic mechanisms to gene-directed therapy. (1999) (205)
- 2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. (1994) (204)
- Targeted therapy in non-small-cell lung cancer—is it becoming a reality? (2010) (203)
- Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. (2010) (200)
- Idiopathic multicentric Castleman's disease: a systematic literature review. (2016) (197)
- Sweet's syndrome and malignancy. (1987) (194)
- Mycosis fungoides and Sezary syndrome. (1996) (193)
- Review of precision cancer medicine: Evolution of the treatment paradigm. (2020) (189)
- PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers (2011) (187)
- Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. (2007) (187)
- MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. (2014) (185)
- Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors (2018) (184)
- A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas (2012) (183)
- HER2 aberrations in cancer: implications for therapy. (2014) (182)
- Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. (2016) (182)
- A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease (2013) (181)
- Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms. (1993) (180)
- Pharmacokinetics, Single-Dose Tolerance, and Biological Activity of Recombinant γ-lnterferon in Cancer Patients (1985) (179)
- International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. (2018) (179)
- A Phase I Study of Weekly R1507, A Human Monoclonal Antibody Insulin-like Growth Factor-I Receptor Antagonist, in Patients with Advanced Solid Tumors (2010) (179)
- Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors. (2016) (179)
- The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity. (1985) (178)
- Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors (2012) (177)
- Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). (1992) (175)
- Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses (2014) (173)
- Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. (1995) (173)
- Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials (2008) (173)
- Expression of p21ras in fresh primary and metastatic human colorectal tumors. (1985) (169)
- Development of curcumin as an epigenetic agent (2010) (168)
- Association of sebaceous gland tumors and internal malignancy: the Muir-Torre syndrome. (1991) (168)
- Phase I Study of Epigenetic Modulation with 5-Azacytidine and Valproic Acid in Patients with Advanced Cancers (2008) (164)
- Successful treatment of Erdheim-Chester disease, a non–Langerhans-cell histiocytosis, with interferon-α (2005) (163)
- Prognostic factor analysis in mycosis fungoides/Sézary syndrome. (1999) (162)
- Sweet's syndrome and cancer and cancer (1993) (162)
- Phase 1b‐2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum‐resistant or platinum‐refractory epithelial ovarian cancer (2011) (160)
- BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. (2015) (160)
- A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors (2012) (160)
- Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor–Based Immunotherapy (2017) (158)
- Sweet's syndrome: a neutrophilic dermatosis classically associated with acute onset and fever. (2000) (157)
- Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. (2004) (157)
- A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies (2010) (156)
- The clinical significance of tumor necrosis factor-α plasma level in patients having chronic lymphocytic leukemia (2002) (156)
- Molecular tumor board: the University of California-San Diego Moores Cancer Center experience. (2014) (154)
- FGFR1 and NTRK3 actionable alterations in “Wild-Type” gastrointestinal stromal tumors (2016) (150)
- Phase I study of recombinant human interleukin-3 in patients with bone marrow failure. (1991) (149)
- A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors (2020) (149)
- Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. (2015) (145)
- Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. (2008) (144)
- Association of Sebaceous Gland Tumors and Internal Malignancy: The Muir-Torre Syndrome (1991) (144)
- The BCR gene and philadelphia chromosome-positive leukemogenesis. (2001) (141)
- Novel Therapeutic Targets in Non-small Cell Lung Cancer (2011) (141)
- Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. (2006) (141)
- RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients (2016) (140)
- Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia. (1991) (140)
- A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors (2013) (139)
- BRAF Mutant Gastrointestinal Stromal Tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance (2013) (138)
- Castleman's disease: from basic mechanisms to molecular therapeutics. (2011) (137)
- A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors (2014) (136)
- Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy (2019) (135)
- Sweet syndrome in patients with solid tumors (1993) (134)
- STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial. (2018) (134)
- Cutaneous paraneoplastic syndromes in solid tumors. (1995) (134)
- Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. (2003) (134)
- Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). (2011) (132)
- Phase II study of alemtuzumab in chronic lymphoproliferative disorders (2003) (130)
- Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab (2017) (127)
- Decitabine Effect on Tumor Global DNA Methylation and Other Parameters in a Phase I Trial in Refractory Solid Tumors and Lymphomas (2009) (127)
- Nuclear factor-κB maintains TRAIL resistance in human pancreatic cancer cells (2006) (126)
- Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial. (2011) (126)
- Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced Solid Tumors (2011) (125)
- Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome. (2004) (125)
- Sweet’s Syndrome (2002) (123)
- Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia (1991) (123)
- Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay (2015) (123)
- Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy (2020) (122)
- A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors (2010) (122)
- Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics. (2005) (120)
- Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients (2016) (119)
- Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. (2017) (119)
- Prognostic Value of Serum Interleukin-6 in Diffuse Large-cell Lymphoma (1997) (118)
- Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer. (2016) (118)
- Phase I Trial of Cixutumumab Combined with Temsirolimus in Patients with Advanced Cancer (2011) (118)
- MS-275 Sensitizes TRAIL-Resistant Breast Cancer Cells, Inhibits Angiogenesis and Metastasis, and Reverses Epithelial-Mesenchymal Transition In vivo (2010) (118)
- Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma (2012) (117)
- A new familial immunodeficiency disorder characterized by severe neutropenia, a defective marrow release mechanism, and hypogammaglobulinemia. (1990) (117)
- The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high‐risk myelodysplastic syndromes (2008) (116)
- The Conundrum of Genetic “Drivers” in Benign Conditions (2016) (114)
- Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse (2010) (112)
- Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma (2013) (111)
- A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer (2011) (110)
- Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms. (2014) (110)
- Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies. (1994) (109)
- Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma (2017) (109)
- Second cancer risk in hairy cell leukemia: analysis of 350 patients. (1997) (108)
- The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians. (2020) (108)
- Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? (2010) (108)
- BRAF(V600) Inhibitor GSK2118436 Targeted Inhibition of Mutant BRAF in Cancer Patients Does Not Impair Overall Immune Competency (2012) (107)
- The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. (2002) (106)
- A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. (2007) (106)
- Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. (2011) (104)
- Pentostatin therapy of T-cell lymphomas with cutaneous manifestations. (1999) (104)
- Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alpha. (2005) (103)
- Cancer: the road to Amiens. (2009) (103)
- Expression of the macrophage colony‐stimulating factor and its receptor in gynecologic malignancies (1991) (102)
- Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy (2016) (101)
- Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement of p53. (2002) (101)
- Molecular epidemiology, cancer-related symptoms, and cytokines pathway. (2008) (101)
- Combined modality therapy for cutaneous T-cell lymphoma. (1996) (101)
- Analysis of breakpoints within the bcr gene and their correlation with the clinical course of Philadelphia-positive chronic myelogenous leukemia. (1988) (101)
- Sweet's syndrome and cancer. (1993) (98)
- P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy (2013) (97)
- Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors (2014) (97)
- Clinical manifestations of vasculitis in patients with solid tumors. A case report and review of the literature. (1994) (96)
- Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders. (2015) (96)
- A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer. (2006) (96)
- BRAF Mutations in Advanced Cancers: Clinical Characteristics and Outcomes (2011) (95)
- Pharmacokinetics, single-dose tolerance, and biological activity of recombinant gamma-interferon in cancer patients. (1985) (95)
- Activation or suppression of the tumoricidal properties of monocytes from cancer patients following treatment with human recombinant gamma-interferon. (1986) (95)
- Equipoise lost: ethics, costs, and the regulation of cancer clinical research. (2010) (93)
- Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications (2015) (93)
- Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma (2019) (93)
- Tripe palms and malignancy. (1989) (92)
- Therapy of chronic myelogenous leukemia with recombinant interferon-gamma. (1987) (91)
- Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. (2021) (91)
- Leukemia‐inhibitory factor stimulates breast, kidney and prostate cancer cell proliferation by paracrine and autocrine pathways (1996) (90)
- Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center (2012) (90)
- Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity (1991) (90)
- Constitutive expression of leukemia inhibitory factor RNA by human bone marrow stromal cells and modulation by IL-1, TNF-alpha, and TGF-beta. (1991) (90)
- Philadelphia chromosome-negative chronic myelogenous leukemia without breakpoint cluster region rearrangement: a chronic myeloid leukemia with a distinct clinical course. (1990) (90)
- Body Composition, Symptoms, and Survival in Advanced Cancer Patients Referred to a Phase I Service (2012) (89)
- Interleukin-10 in non-Hodgkin's lymphoma. (1997) (88)
- Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing. (2017) (88)
- Fludarabine therapy in macroglobulinemic lymphoma. (1990) (88)
- Next generation predictive biomarkers for immune checkpoint inhibition (2017) (88)
- Sweet's syndrome: a review of current treatment options. (2002) (88)
- PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes (2012) (88)
- Acute febrile neutrophilic dermatosis. (1989) (88)
- Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies (2015) (87)
- ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy (2020) (87)
- Expression of c-abl in Philadelphia-positive acute myelogenous leukemia. (1987) (86)
- Cytokine deregulation in cancer. (2001) (86)
- Phase I study of multiple dose intramuscularly administered recombinant gamma interferon. (1986) (86)
- On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients (2015) (86)
- Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine (2017) (86)
- Targeted therapy in non-small-cell lung cancer—is it becoming a reality? (2011) (86)
- Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors. (1992) (86)
- Molecular landscape of pancreatic cancer: implications for current clinical trials (2015) (85)
- Lymphotoxin is an autocrine growth factor for Epstein-Barr virus- infected B cell lines (1993) (85)
- Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial. (2009) (84)
- Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary. (2017) (84)
- Vasculitis and cancer. (1993) (84)
- Phase I Study of the Antiangiogenic Antibody Bevacizumab and the mTOR/Hypoxia-Inducible Factor Inhibitor Temsirolimus Combined with Liposomal Doxorubicin: Tolerance and Biological Activity (2012) (84)
- Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center (2017) (83)
- VEGF-A Expression Correlates with TP53 Mutations in Non-Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy. (2015) (83)
- Clinical correlates of elevated serum levels of interleukin 6 in patients with untreated Hodgkin's disease. (1997) (83)
- Risks and benefits of phase 1 oncology trials, revisited. (2005) (82)
- BCR rearrangement-negative chronic myelogenous leukemia revisited. (2001) (82)
- Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing (2014) (82)
- LIF: not just a leukemia inhibitory factor. (1991) (81)
- Community-acquired methicillin-resistant Staphylococcus aureus skin infection: an emerging clinical problem. (2004) (81)
- Aurora Kinase Inhibitors in Oncology Clinical Trials: Current State of the Progress. (2015) (80)
- A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC) (2008) (79)
- Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience (2012) (79)
- Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes (2003) (79)
- Phase I Trial of a Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Advanced Malignancies (2009) (78)
- Rearrangement in the breakpoint cluster region and the clinical course in Philadelphia-negative chronic myelogenous leukemia. (1986) (78)
- Alteration in bone marrow adherent layer growth factor expression: a novel mechanism of chronic myelogenous leukemia progression. (1991) (77)
- Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. (2012) (77)
- Treatment of poor-prognosis, newly diagnosed acute myeloid leukemia with ara-C and recombinant human granulocyte-macrophage colony-stimulating factor. (1990) (75)
- Effects of low doses of recombinant human granulocyte‐macrophage colony stimulating factor (GM‐CSF) in patients with myelodysplastic syndromes (1991) (75)
- Response of histiocytoses to imatinib mesylate: fire to ashes. (2010) (75)
- Recombinant gamma interferon induces hypertriglyceridemia and inhibits post-heparin lipase activity in cancer patients (1986) (74)
- Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. (2006) (74)
- Precision oncology: the UC San Diego Moores Cancer Center PREDICT experience. (2015) (74)
- BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System (2016) (73)
- Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. (2012) (73)
- A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation. (2000) (73)
- Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art (2014) (73)
- Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. (2015) (72)
- Mechanistic Basis for Overcoming Platinum Resistance Using Copper Chelating Agents (2012) (72)
- Erythromelalgia and myeloproliferative disorders. (1989) (71)
- Effects of granulocyte-macrophage colony-stimulating factor in iatrogenic myelosuppression, bone marrow failure, and regulation of host defense. (1990) (71)
- Mucocutaneous paraneoplastic manifestations of hematologic malignancies. (1995) (71)
- Cell-Free DNA from Ascites and Pleural Effusions: Molecular Insights into Genomic Aberrations and Disease Biology (2017) (71)
- Survival of patients in a Phase 1 clinic (2009) (69)
- Analysis of 1,115 Patients Tested for MET Amplification and Therapy Response in the MD Anderson Phase I Clinic (2014) (69)
- Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase. (1993) (69)
- Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience (2016) (69)
- Targeted Morphoproteomic Profiling of Ewing's Sarcoma Treated with Insulin-Like Growth Factor 1 Receptor (IGF1R) Inhibitors: Response/Resistance Signatures (2011) (68)
- Sulforaphane inhibits angiogenesis through activation of FOXO transcription factors. (2009) (68)
- Alterations in tretinoin pharmacokinetics following administration of liposomal all-trans retinoic acid. (1996) (68)
- Factors associated with failure of oncology drugs in late-stage clinical development: A systematic review. (2017) (68)
- Phase II studies of recombinant human interferon gamma in metastatic renal cell carcinoma. (1987) (67)
- Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma (2018) (67)
- 2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. (1994) (67)
- Mucocutaneous paraneoplastic syndromes. (1997) (67)
- Cytokine Genes and Pain Severity in Lung Cancer: Exploring the Influence of TNF-α-308 G/A IL6-174G/C and IL8-251T/A (2007) (67)
- TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics (2016) (67)
- Therapy of chronic myelogenous leukemia: chemotherapy and interferons. (1988) (66)
- Poor prognosis in non-Caucasian patients with early-onset mycosis fungoides. (2009) (66)
- Overcoming Platinum Resistance through the Use of a Copper-Lowering Agent (2012) (66)
- Erdheim-Chester disease: characteristics and management. (2014) (65)
- Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma. (2003) (65)
- Consensus Recommendations to Accelerate Clinical Trials for Neurofibromatosis Type 2 (2009) (65)
- Differential expression of p21ras gene products among histological subtypes of fresh primary human lung tumors. (1986) (65)
- Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade (2018) (65)
- Reproducibility of CT perfusion parameters in liver tumors and normal liver. (2011) (64)
- Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer. (2011) (64)
- Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity. (1998) (64)
- Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-α-resistant hairy cell leukemia: 7-year follow-up (1997) (64)
- Erythema gyratum repens. (1995) (64)
- Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms (2014) (63)
- Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial (2013) (63)
- BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease (2014) (63)
- First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies (2015) (63)
- BAP1: Not just a BRCA1-associated protein. (2020) (62)
- Successful Treatment of Castleman's Disease with Interleukin-1 Receptor Antagonist (Anakinra) (2010) (62)
- Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. (2018) (62)
- Precision oncology for patients with advanced cancer: the challenges of malignant snowflakes (2015) (62)
- Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation. (2013) (62)
- All-trans retinoic acid: tolerance and biologic effects in myelodysplastic syndrome. (1993) (61)
- Elevated plasma thrombopoietic activity in patients with metastatic cancer-related thrombocytosis. (1995) (60)
- Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma (2017) (60)
- Outcomes of research biopsies in phase I clinical trials: the MD anderson cancer center experience. (2011) (60)
- Pilot study of low-dose interleukin-11 in patients with bone marrow failure. (2001) (60)
- Tripe palms and cancer. (1993) (59)
- Analysis of P210bcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients. (1987) (59)
- Reproducibility of perfusion parameters in dynamic contrast-enhanced MRI of lung and liver tumors: effect on estimates of patient sample size in clinical trials and on individual patient responses. (2010) (59)
- Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes. (2005) (59)
- International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. (2020) (59)
- Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis. (1995) (59)
- Erythromelalgia: review of clinical characteristics and pathophysiology. (1991) (58)
- Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a xenograft human pancreatic cancer model. (2009) (57)
- High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations (2017) (57)
- Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study (2019) (57)
- Next‐Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma (2018) (57)
- Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer (2015) (57)
- Phase I trials as valid therapeutic options for patients with cancer (2019) (56)
- Reproducibility of perfusion parameters obtained from perfusion CT in lung tumors. (2011) (56)
- Genomic Landscape of Malignant Mesotheliomas (2016) (56)
- Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer (2019) (56)
- Breast Cancer Experience of the Molecular Tumor Board at the University of California, San Diego Moores Cancer Center. (2015) (55)
- Autocrine interleukin-1beta production in leukemia: evidence for the involvement of mutated RAS. (1999) (55)
- Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice (2009) (55)
- Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436). (2014) (55)
- Recombinant interferon gamma in hairy cell leukemia, multiple myeloma, and Waldenstrom's macroglobulinemia (1988) (55)
- Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours. (2017) (55)
- Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma (2015) (55)
- Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib. (2008) (55)
- Abnormalities in the PRAD1 (CYCLIN D1 / BCL‐1) oncogene are frequent in cervical and vulvar squamous cell carcinoma cell lines (1995) (54)
- Squamousness: Next-generation sequencing reveals shared molecular features across squamous tumor types (2015) (54)
- Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients (2017) (54)
- Erdheim-Chester Disease of the Central Nervous System: New Manifestations of a Rare Disease (2011) (54)
- Genome-Wide Sequencing of Cell-Free DNA Identifies Copy-Number Alterations That Can Be Used for Monitoring Response to Immunotherapy in Cancer Patients (2018) (54)
- Leukemia inhibitory factor binds to human breast cancer cells and stimulates their proliferation. (1995) (54)
- Unique molecular landscapes in cancer: implications for individualized, curated drug combinations. (2014) (54)
- Pertuzumab + trastuzumab for HER2-positive metastatic biliary cancer: Preliminary data from MyPathway. (2017) (53)
- Molecular landscape of prostate cancer: implications for current clinical trials. (2015) (53)
- Prevalence of complementary medicine use in a phase 1 clinical trials program (2011) (53)
- Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer. (2015) (52)
- Identification of molecular variants of p210bcr-abl in chronic myelogenous leukemia (1987) (52)
- Granulocyte‐macrophage colony‐stimulating factor as a cause of paraneoplastic leukaemoid reaction in advanced transitional cell carcinoma (1993) (52)
- Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. (2015) (52)
- Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial (2019) (52)
- Cutaneous castleman's disease responds to anti–interleukin-6 treatment (2007) (52)
- Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients (2019) (51)
- The Influence of Tumor Necrosis Factor-α −308 G/A and IL-6 −174 G/C on Pain and Analgesia Response in Lung Cancer Patients Receiving Supportive Care (2008) (51)
- Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors. (2010) (51)
- First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-κΒ and p70s6k, in patients with advanced solid tumors (2014) (51)
- NF2/Merlin in hereditary neurofibromatosis 2 versus cancer: biologic mechanisms and clinical associations (2013) (51)
- Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm (2016) (51)
- Philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia. (1990) (51)
- Cytokine expression in adherent layers from patients with myelodysplastic syndrome and acute myelogenous leukemia. (1995) (51)
- Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers (2014) (50)
- Response to interferon-alpha in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine. (1995) (50)
- Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience (2014) (50)
- Clinical and laboratory changes induced by alpha interferon in chronic lymphocytic leukemia‐a pilot study (1987) (50)
- Uncommon tumors and exceptional therapies: paradox or paradigm? (2007) (50)
- High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphoma. (1998) (50)
- Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study. (2011) (50)
- Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib (2008) (50)
- Appearance of acute leukemia-associated P190BCR-ABL in chronic myelogenous leukemia may correlate with disease progression. (1991) (50)
- MHC-I genotype and tumor mutational burden predict response to immunotherapy (2020) (49)
- Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining “Actionability” of a Molecular Lesion and Patient Management Support (2017) (49)
- Salirasib in the treatment of pancreatic cancer. (2010) (49)
- Interferon therapy for orbital infiltration secondary to Erdheim-Chester disease. (2001) (48)
- Salivary duct carcinoma: targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus. (2011) (48)
- A Phase I Trial of Liposomal Doxorubicin, Bevacizumab, and Temsirolimus in Patients with Advanced Gynecologic and Breast Malignancies (2011) (48)
- Erythropoietin treatment in patients with myelodysplastic syndrome and anemia. (1991) (48)
- Philadelphia-negative chronic myelogenous leukemia with breakpoint cluster region rearrangement: molecular analysis, clinical characteristics, and response to therapy. (1988) (48)
- Cytokine deregulation in hematological malignancies: clinical and biological implications. (1997) (47)
- GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia (1998) (47)
- A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease (2015) (47)
- Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: A phase I trial of bortezomib plus bevacizumab (2014) (47)
- Phase II clinical trial of curcumin in patients with advanced pancreatic cancer. (2006) (47)
- Predictive Value of Phase I Trials for Safety in Later Trials and Final Approved Dose: Analysis of 61 Approved Cancer Drugs (2013) (47)
- Hepatic arterial infusion chemotherapy for metastatic colorectal cancer: a concise overview. (2004) (47)
- Timing of palliative care referral and symptom burden in phase 1 cancer patients (2010) (47)
- Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience. (2005) (46)
- Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics (2015) (46)
- First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors (2019) (46)
- BRAF mutation testing with a rapid, fully integrated molecular diagnostics system (2015) (46)
- Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist (2012) (46)
- KRASness and PIK3CAness in Patients with Advanced Colorectal Cancer: Outcome after Treatment with Early-Phase Trials with Targeted Pathway Inhibitors (2012) (46)
- From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm. (2020) (45)
- Phase I study of a combination of recombinant interferon-alpha and recombinant interferon-gamma in cancer patients. (1986) (45)
- Muir-Torre syndrome. (1995) (45)
- Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design (2016) (45)
- Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA (2019) (45)
- Combining targeted therapies: practical issues to consider at the bench and bedside. (2010) (45)
- Molecular characteristics of chronic myelogenous leukemia in blast crisis. (1987) (45)
- Phase 1 first-in-human clinical study of S-trans, trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors (2009) (45)
- First-in-human study of AMG 655, a pro-apoptotic TRAIL receptor-2 agonist, in adult patients with advanced solid tumors (2007) (45)
- Somatic genomic landscape of over 15,000 patients with advanced-stage cancer from clinical next-generation sequencing analysis of circulating tumor DNA. (2016) (45)
- Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers (2016) (44)
- Fool’s gold, lost treasures, and the randomized clinical trial (2013) (44)
- Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies (2013) (44)
- Mycobacterial pulmonary infections after allogeneic bone marrow transplantation. (1984) (44)
- Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics (2015) (44)
- Precision medicine: lessons learned from the SHIVA trial. (2015) (44)
- KBM-7, a human myeloid leukemia cell line with double Philadelphia chromosomes lacking normal c-ABL and BCR transcripts. (1995) (44)
- Miscellaneous genodermatoses: Beckwith-Wiedemann syndrome, Birt-Hogg-Dube syndrome, familial atypical multiple mole melanoma syndrome, hereditary tylosis, incontinentia pigmenti, and supernumerary nipples. (1995) (44)
- APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy (2018) (44)
- Genetics on a WHIM (2014) (43)
- Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus (2018) (43)
- It's About Time: Lessons for Solid Tumors from Chronic Myelogenous Leukemia Therapy (2012) (43)
- Minimal residual disease in interferon-treated chronic myelogenous leukemia: results and pitfalls of analysis based on polymerase chain reaction. (1992) (43)
- Altered levels of interleukin-1 beta and interleukin-1 receptor antagonist in chronic myelogenous leukemia: clinical and prognostic correlates. (1994) (43)
- Genetic and nongenetic covariates of pain severity in patients with adenocarcinoma of the pancreas: assessing the influence of cytokine genes. (2009) (43)
- Ubiquitous expression of cytokines in diverse leukemias of lymphoid and myeloid lineage. (1993) (43)
- Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies (2017) (43)
- Z-138: a new mature B-cell acute lymphoblastic leukemia cell line from a patient with transformed chronic lymphocytic leukemia. (1998) (43)
- Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response (2015) (42)
- Novel in vivo imaging shows up-regulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies (2006) (42)
- A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies. (2013) (42)
- Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies (2019) (42)
- Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway (2014) (41)
- Myelokathexis: normalization of neutrophil counts and morphology by GM-CSF. (1992) (41)
- Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside. (2012) (41)
- Significance and correlations of molecular analysis results in patients with Philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia. (1988) (41)
- Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib. (2008) (41)
- R1507, an Anti-Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antibody, and EWS/FLI-1 siRNA in Ewing's Sarcoma: Convergence at the IGF/IGFR/Akt Axis (2011) (41)
- Interferon-a Therapy for Chronic Myelogenous Leukemia (1995) (41)
- Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) (2021) (40)
- Safety and pharmacokinetics of AMG 706 in patients with advanced solid tumors (2005) (40)
- Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies (2019) (40)
- Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics (2017) (40)
- A phase I study of q3W R1507, a human monoclonal antibody IGF-1R antagonist in patients with advanced cancer (2007) (40)
- Epstein-Barr virus in patients with chronic lymphocytic leukemia: A pilot study (2006) (40)
- Safety, pharmacokinetics, and activity of EZN‐2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies (2012) (39)
- Recombinant interferon-alpha therapy of Philadelphia chromosome-negative myeloproliferative disorders with thrombocytosis. (1989) (39)
- A Phase I Clinical Trial of Darinaparsin in Patients with Refractory Solid Tumors (2009) (39)
- Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: Phase 1 dose-escalation study (2014) (39)
- Chronic myelogenous leukemia and sweet syndrome (1989) (39)
- Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy (2016) (38)
- Phase 1-2 trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitor trametinib (T) in BRAF V600 mutant colorectal cancer (CRC): Updated efficacy and biomarker analysis. (2014) (38)
- Biomarker-directed therapy of squamous carcinomas of the head and neck: targeting PI3K/PTEN/mTOR pathway. (2013) (38)
- Challenging Standard-of-Care Paradigms in the Precision Oncology Era. (2018) (38)
- Phase 1 clinical trials for sarcomas: the cutting edge (2011) (38)
- Challenges and perspective of drug repurposing strategies in early phase clinical trials (2015) (38)
- Human epidermal receptor 2–amplified salivary duct carcinoma: Regression with dual human epidermal receptor 2 inhibition and anti–vascular endothelial growth factor combination treatment (2014) (38)
- Farnesyltransferase inhibitors: where are we now? (2010) (38)
- Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival (2018) (37)
- A phase I dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignancies (2007) (37)
- The pathogenesis of Sweet's syndrome. (1991) (37)
- Pertuzumab + trastuzumab for HER2-amplified/overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway. (2017) (37)
- Genomic portfolio of Merkel cell carcinoma as determined by comprehensive genomic profiling: implications for targeted therapeutics (2016) (37)
- Differential dose‐related haematological effects of GM‐CSF in pancytopenia: evidence supporting the advantage of low‐ over high‐dose administration in selected patients (1991) (37)
- Analysis of MDM2 Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies (2018) (37)
- Phase I Clinical Trial of MPC-6827 (Azixa), a Microtubule Destabilizing Agent, in Patients with Advanced Cancer (2010) (37)
- Thymoma Patients Treated in a Phase I Clinic at MD Anderson Cancer Center: Responses to mTOR Inhibitors and Molecular Analyses (2013) (37)
- Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome. (2002) (37)
- Paclitaxel activity for the treatment of non‐Hodgkin's lymphoma: final report of a phase II trial (1997) (37)
- Phase I Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine Phosphatase Inhibitor, Combined with Interferon Alpha for Patients with Solid Tumors (2011) (36)
- Body composition and survival in the early clinical trials setting. (2013) (36)
- Transformation of Human Mesenchymal Cells and Skin Fibroblasts into Hematopoietic Cells (2011) (36)
- Final results from a phase I, dose-escalation study of PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase. (2010) (36)
- Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors (2017) (36)
- Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas. (2004) (36)
- Morphoproteomic Profiling of the Mammalian Target of Rapamycin (mTOR) Signaling Pathway in Desmoplastic Small Round Cell Tumor (EWS/WT1), Ewing’s Sarcoma (EWS/FLI1) and Wilms’ Tumor(WT1) (2013) (36)
- Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. (2018) (35)
- Combining Curcumin (Diferuloylmethane) and Heat Shock Protein Inhibition for Neurofibromatosis 2 Treatment: Analysis of Response and Resistance Pathways (2011) (35)
- Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors (2016) (35)
- Dosing Three-Drug Combinations That Include Targeted Anti-Cancer Agents: Analysis of 37,763 Patients. (2017) (35)
- OBSTRUCTIVE LUNG DISEASE AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION (1984) (35)
- Genomic landscape of salivary gland tumors (2015) (35)
- Targeted therapy in rare cancers—adopting the orphans (2012) (35)
- Phase II study of XL184 in a cohort of patients (pts) with castration-resistant prostate cancer (CRPC) and measurable soft tissue disease. (2010) (34)
- Role of granulocyte‐macrophage colony‐stimulating factor in Philadelphia (Ph1)‐positive acute lymphoblastic leukemia: Studies on two newly established Ph1‐positive acute lymphoblastic leukemia cell lines (Z‐119 and Z‐181) (1996) (34)
- Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience. (2009) (34)
- Synthetic lethality-mediated precision oncology via the tumor transcriptome (2021) (34)
- Androgen receptors beyond prostate cancer: an old marker as a new target (2014) (34)
- MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis (2018) (34)
- A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors (2011) (33)
- Cetuximab-Associated Elongation of the Eyelashes (2011) (33)
- GNAS, GNAQ, and GNA11 alterations in patients with diverse cancers (2018) (33)
- Personalized medicine in a phase I clinical trials program: The M. D. Anderson Cancer Center Initiative. (2011) (33)
- Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials. (2020) (33)
- The role of investigational therapy in management of patients with advanced metastatic malignancy. (2009) (33)
- Combining Erlotinib and Cetuximab Is Associated with Activity in Patients with Non–Small Cell Lung Cancer (Including Squamous Cell Carcinomas) and Wild-Type EGFR or Resistant Mutations (2013) (33)
- Outcome analyses after the first admission to an intensive care unit in patients with advanced cancer referred to a phase I clinical trials program. (2011) (33)
- Merkel cell polyomavirus and HPV-17 associated with cutaneous squamous cell carcinoma arising in a patient with melanoma treated with the BRAF inhibitor dabrafenib. (2013) (33)
- Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies (2014) (33)
- Interferon-stimulated genes in interferon-sensitive and -resistant chronic myelogenous leukemia patients. (1992) (33)
- Phosphatidylinositol 3‐kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities (2018) (32)
- Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine (2019) (32)
- Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns (2017) (32)
- Very low doses of GM-CSF administered alone or with erythropoietin in aplastic anemia. (1992) (32)
- Myelodysplastic syndrome overview. (2002) (32)
- Phase I first-in-human study of the PI3 kinase inhibitor GSK2126458 (GSK458) in patients with advanced solid tumors (study P3K112826). (2011) (32)
- Advanced basal cell cancer: concise review of molecular characteristics and novel targeted and immune therapeutics (2018) (32)
- Results from a phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1{alpha}. (2010) (32)
- Evaluation of the Clinical Relevance of Body Composition Parameters in Patients With Cancer Metastatic to the Liver Treated With Hepatic Arterial Infusion Chemotherapy (2012) (32)
- Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach (2017) (32)
- Novel Secondary Somatic Mutations in Ewing's Sarcoma and Desmoplastic Small Round Cell Tumors (2014) (32)
- Metaplastic breast cancers: Genomic profiling, mutational burden and tumor-infiltrating lymphocytes. (2019) (32)
- Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. (2013) (32)
- Dual EGFR inhibition in combination with anti-VEGF treatment: A phase I clinical trial in non-small cell lung cancer (2013) (31)
- Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials (2018) (31)
- Transformation of chronic lymphocytic leukemia to lymphoma of true histiocytic type (1995) (31)
- CML: mechanisms of disease initiation and progression. (1993) (31)
- Survival of patients in a phase I clinic: The M. D. Anderson Cancer Center experience (2008) (31)
- Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non–Small Cell Lung Cancer Patients (2016) (31)
- A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer (2010) (31)
- High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers (2020) (31)
- Reduced focal adhesion kinase and paxillin phosphorylation in BCR‐ABL‐transfected cells (2002) (31)
- Triple-Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents (2014) (31)
- Molecular profiling and the reclassification of cancer: divide and conquer. (2013) (31)
- Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours (2017) (31)
- Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival (2019) (30)
- Non-small-cell lung cancer with HER2 exon 20 mutation: regression with dual HER2 inhibition and anti-VEGF combination treatment. (2013) (30)
- Dosing targeted and cytotoxic two‐drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013 (2016) (30)
- Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance (2015) (30)
- The Marriage Between Genomics and Immunotherapy: Mismatch Meets Its Match (2018) (30)
- Cell-Cycle Gene Alterations in 4,864 Tumors Analyzed by Next-Generation Sequencing: Implications for Targeted Therapeutics (2016) (30)
- Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies (2019) (30)
- Effect of differentiation‐inducing agents on oncogene expression in a chronic myelogenous leukemia cell line (1988) (30)
- Cyclin alterations in diverse cancers: outcome and co-amplification network (2014) (30)
- Hybridization protection assay: a rapid, sensitive, and specific method for detection of Philadelphia chromosome-positive leukemias. (1991) (30)
- Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs. (2012) (30)
- Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus (2014) (29)
- Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies (2013) (29)
- Pediatric patients with refractory central nervous system tumors: experiences of a clinical trial combining bevacizumab and temsirolimus. (2014) (29)
- Universal Genomic Testing Needed to Win the War Against Cancer: Genomics IS the Diagnosis. (2016) (29)
- Next Generation Sequencing Reveals Potentially Actionable Alterations in the Majority of Patients with Lymphoid Malignancies. (2016) (29)
- Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease (2017) (29)
- Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity (2020) (29)
- Extracutaneous manifestations of Sweet's syndrome: steroid-responsive culture-negative pulmonary lesions. (1992) (29)
- SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer. (2015) (29)
- Phase I trial of valproic acid and lenalidomide in patients with advanced cancer (2015) (28)
- A phase I study of MDM2 antagonist RG7112 in patients (pts) with relapsed/refractory solid tumors. (2012) (28)
- Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress? (2019) (28)
- Phase I study of i.v. administered recombinant gamma interferon in cancer patients. (1986) (28)
- Polycystic ovary syndrome in men: Stein-Leventhal syndrome revisited. (2007) (28)
- Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer. (2013) (28)
- Diagnosing the Sweet syndrome. (1989) (28)
- Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors (2020) (28)
- Turmeric and Green Tea: A Recipe for the Treatment of B-Chronic Lymphocytic Leukemia (2009) (28)
- Cell cycle-related shifts in subcellular localization of BCR: association with mitotic chromosomes and with heterochromatin. (1995) (28)
- Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer (2015) (28)
- Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma (2017) (28)
- A phase lb, open-label, multicenter, dose-escalation study of the oral pan-PI3K inhibitor BKM120 in combination with the oral MEK1/2 inhibitor GSK1120212 in patients (pts) with selected advanced solid tumors. (2012) (28)
- A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5‐fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver (2010) (28)
- An appraisal of drug development timelines in the Era of precision oncology (2016) (28)
- Targeted Therapy of Advanced Gallbladder Cancer and Cholangiocarcinoma with Aggressive Biology: Eliciting Early Response Signals from Phase 1 trials (2013) (28)
- A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumors. (2010) (28)
- Mutated TP53 is a marker of increased VEGF expression: analysis of 7,525 pan-cancer tissues (2019) (28)
- A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R): Implications for Inhibition of the IGF-1R signal (2013) (28)
- Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers (2020) (28)
- The Urgent Need for Clinical Research Reform to Permit Faster, Less Expensive Access to New Therapies for Lethal Diseases (2015) (28)
- MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit (2014) (28)
- A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies (2013) (27)
- A framework for genomic biomarker actionability and its use in clinical decision making (2014) (27)
- Prospective Blinded Study of BRAFV600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders (2014) (27)
- Trisomy 12 correlates with elevated expression of p21 ras in a human adenosquamous carcinoma of the lung. (1986) (27)
- Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and PIK3CA Mutations (2013) (27)
- Eyelash trichomegaly: review of congenital, acquired, and drug‐associated etiologies for elongation of the eyelashes (2012) (27)
- Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines (2015) (27)
- Phase I dose-escalation of the oral MEK1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral AKT inhibitor GSK2141795 (GSK795). (2011) (27)
- Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein Enbrel in patients with refractory hematologic malignancies (2002) (27)
- Update on therapeutic options for chronic myelogenous leukemia. (1990) (26)
- A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors (2013) (26)
- MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors (2013) (26)
- Equipoise abandoned? Randomization and clinical trials. (2013) (26)
- Leukemia Inhibitory Factor in Long-Term Adherent Layer Cultures: Increased Levels of Bioactive Protein in Leukemia and Modulation by IL-4, IL-1β, and TNF-α (1994) (26)
- Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer (2013) (26)
- Bone marrow hypoplasia and aplasia complicating interferon therapy for chronic myelogenous leukemia (1992) (26)
- Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy (2020) (26)
- Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing (2018) (26)
- A phase II study alternating alpha‐2a‐interferon and gamma‐interferon therapy in patients with chronic myelogenous leukemia (1991) (26)
- Long-term results in a cohort of medullary thyroid cancer (MTC) patients (pts) in a phase I study of XL184 (BMS 907351), an oral inhibitor of MET, VEGFR2, and RET. (2010) (26)
- Activity of interferon‐α and isotretinoin in patients with advanced, refractory lymphoid malignancies (2004) (26)
- A phase II basket trial of Dual Anti–CTLA–4 and Anti–PD–1 Blockade in Rare Tumors (DART) SWOG S1609: High‐grade neuroendocrine neoplasm cohort (2021) (26)
- Pilot study of regional, hepatic intra‐arterial paclitaxel in patients with breast carcinoma metastatic to the liver (2007) (26)
- Interleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1α antibody, in a phase III randomized study of advanced colorectal cancer (2018) (26)
- Cimetidine therapy of herpes simplex virus infections in immunocompromised patients (1987) (25)
- Phase I Clinical Trial Outcomes in 93 Patients with Brain Metastases: The MD Anderson Cancer Center Experience (2011) (25)
- Constitutive and induced expression of growth factors in normal and chronic phase chronic myelogenous leukemia Ph1 bone marrow stroma. (1990) (25)
- Targeting ARID1A mutations in cancer. (2021) (25)
- Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528 (2013) (25)
- A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma. (2017) (25)
- Evaluation of liposomal curcumin cytochrome p450 metabolism. (2010) (25)
- The Master Observational Trial: A New Class of Master Protocol to Advance Precision Medicine (2020) (25)
- Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer (2017) (25)
- Ewing's sarcoma: overcoming the therapeutic plateau. (2012) (25)
- Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors (2014) (25)
- Altered levels of interleukin-1β and interleukin-1 receptor antagonist in chronic myelogenous leukemia: Clinical and prognostic correlates (1994) (24)
- Phenotypic and Genomic Determinants of Immunotherapy Response Associated with Squamousness (2019) (24)
- Thrombopoietic Factors in Chronic Bone Marrow Failure States: The Platelet Problem Revisited (2005) (24)
- A pilot study of temsirolimus and body composition (2012) (24)
- Advance care planning in patients with cancer referred to a phase I clinical trials program: the MD Anderson Cancer Center experience. (2012) (24)
- Molecular Tumor Boards: Realizing Precision Oncology Therapy (2018) (24)
- Phase I Study of Alternate-Week Administration of Tipifarnib in Patients with Myelodysplastic Syndrome (2008) (24)
- Historical communication: Philadelphia-positive chronic myelogenous leukemia followed for 27 years. (1988) (24)
- Identification of molecular variants of p210bcr-abl in chronic myelogenous leukemia. (1987) (24)
- Dual anti-CTLA-4 and anti-PD-1 blockade in metaplastic carcinoma of the breast: Dart (SWOG S1609, Cohort 36). (2020) (24)
- Identification of targets for prostate cancer immunotherapy (2019) (24)
- Molecular analysis of chromosome 22 breakpoints in adult Philadelphia-positive acute lymphoblastic leukaemia. (1987) (23)
- Click chemistry, 3D-printing, and omics: the future of drug development (2015) (23)
- High-Risk Myelodysplastic Syndrome (MDS): First Results of International Phase 2 Study with Oral Farnesyltransferase Inhibitor R115777 (ZARNESTRATM). (2004) (23)
- Molecular Biology in Cancer Medicine (1999) (23)
- Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors (2017) (23)
- A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer (2014) (23)
- Germline PTPRD Mutations in Ewing Sarcoma: Biologic and Clinical Implications (2013) (23)
- A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma. (2014) (23)
- 379 POSTER A phase I study of XL184, a MET, VEGFR2, and RET kinase inhibitor, administered orally to patients (pts) with advanced malignancies, including a subgroup of pts with medullary thyroid cancer (MTC) (2008) (23)
- Wedding of Molecular Alterations and Immune Checkpoint Blockade: Genomics as a Matchmaker. (2021) (22)
- Chemotherapy resistance and retreatment: a dogma revisited. (2010) (22)
- Activity of cabozantinib (XL184) in metastatic melanoma: Results from a phase II randomized discontinuation trial (RDT). (2012) (22)
- Next-Generation Sequencing in the Clinical Setting Clarifies Patient Characteristics and Potential Actionability. (2017) (22)
- Outcomes of Phase II Clinical Trials with Single-Agent Therapies in Advanced/Metastatic Non–Small Cell Lung Cancer Published between 2000 and 2009 (2012) (22)
- The effects of curcumin (diferuloylmethane) on body composition of patients with advanced pancreatic cancer (2016) (22)
- Interleukin-4 and Interleukin-13 (2003) (22)
- A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer (2015) (22)
- The paradox of cancer genes in non-malignant conditions: implications for precision medicine (2020) (22)
- Understanding Toxicities of Targeted Agents: Implications for Anti-tumor Activity and Management. (2015) (22)
- Timing of palliative care referral and symptom burden in phase I cancer patients: A retrospective cohort study. (2010) (22)
- Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study (2021) (21)
- Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement (2011) (21)
- Phase I Study of a Combination of Recombinant Tumor Necrosis Factor-α and Recombinant Interferon-γ in Cancer Patients (1989) (21)
- Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis (2019) (21)
- A phase I study of R1507, a human monoclonal antibody IGF-1R (insulin-like growth factor receptor) antagonist given weekly in patients with advanced solid tumors (2007) (21)
- Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus (2016) (21)
- Project Zero Delay: a process for accelerating the activation of cancer clinical trials. (2009) (21)
- Activity of cabozantinib (XL184) in metastatic breast cancer (MBC): Results from a phase II randomized discontinuation trial (RDT). (2012) (21)
- Safety and antitumor activity of AMG 706 in patients (pts) with thyroid cancer (TC): A subset analysis from a phase 1 dose-finding study. (2006) (21)
- Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and Screening (2021) (21)
- Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics (2019) (21)
- Telomerase Reverse Transcriptase Promoter Alterations Across Cancer Types as Detected by Next-Generation Sequencing: A Clinical and Molecular Analysis of 423 Patients (2017) (21)
- Suppression of chronic myelogenous leukemia colony growth by interleukin-4. (1993) (21)
- The molecular pathology of chronic myelogenous leukaemia (1991) (21)
- Transcriptomic silencing as a potential mechanism of treatment resistance. (2020) (21)
- Interferon-alpha therapy for chronic myelogenous leukemia. (1995) (21)
- Cytokines: Interleukins and Their Receptors (2011) (21)
- Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy. (2013) (21)
- Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies. (2002) (20)
- Phase II study of low-dose interleukin-11 in patients with myelodysplastic syndrome (2006) (20)
- Fusion of the bcr and the c-abl genes in Ph'-positive acute lymphocytic leukemia with no rearrangement in the breakpoint cluster region. (1988) (20)
- Counterpoint: Successes in the Pursuit of Precision Medicine: Biomarkers Take Credit. (2017) (20)
- Association of concurrent acid-suppression therapy with survival outcomes and adverse event incidence in oncology patients receiving erlotinib (2016) (20)
- A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors (2015) (20)
- First results from a phase I trial of AZD8055, a dual mTORC1 and mTORC2 inhibitor. (2011) (20)
- Apoptosis in chronic myelogenous leukemia: studies of stage-specific differences. (1997) (20)
- Molecular and biologic characterization of a newly established Philadelphia-positive acute lymphoblastic leukemia cell line (Z-33) with an autocrine response to GM-CSF. (1996) (20)
- Epidermal growth factor receptor mutation and diverse tumors: Case report and concise literature review (2010) (20)
- Binding partners for curcumin in human schwannoma cells: biologic implications. (2013) (20)
- Transcriptomics and Solid Tumors: The Next Frontier in Precision Cancer Medicine. (2020) (20)
- Final results of a first-in-human phase I trial of PBI-05204, an inhibitor of AKT, FGF-2, NF-Kb, and p70S6K in advanced cancer patients. (2011) (19)
- The immunocytokine scFv23/TNF targeting HER-2/neu induces synergistic cytotoxic effects with 5-fluorouracil in TNF-resistant pancreatic cancer cell lines. (2008) (19)
- Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. (2012) (19)
- The changing face of Phase 1 cancer clinical trials (2009) (19)
- Targeted therapies: What have we learned from SHIVA? (2016) (19)
- Barriers to study enrollment in patients with advanced cancer referred to a phase I clinical trials unit. (2013) (19)
- Treatment of Sweet's syndrome. (1990) (19)
- CASE 1. Langerhans cell histiocytosis of the thyroid. (2006) (19)
- SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer (2021) (19)
- Phase I Study of BIIB028, a Selective Heat Shock Protein 90 Inhibitor, in Patients with Refractory Metastatic or Locally Advanced Solid Tumors (2013) (19)
- NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys. (2015) (19)
- Phase I Trial of Hepatic Arterial Infusion of Nanoparticle Albumin–Bound Paclitaxel: Toxicity, Pharmacokinetics, and Activity (2011) (19)
- Angiosarcoma heterogeneity and potential therapeutic vulnerability to immune checkpoint blockade: insights from genomic sequencing (2020) (19)
- The modulatory hematopoietic activities of leukemia inhibitory factor. (1992) (19)
- Debunking the Delusion That Precision Oncology Is an Illusion. (2017) (18)
- Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD‐L1 expression in cancer patients (2019) (18)
- Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials (2016) (18)
- MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors. (2015) (18)
- Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity. (1991) (18)
- Phase I dose-escalation study of E7080, a multikinase inhibitor, in patients with advanced solid tumors (2008) (18)
- Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma (2012) (18)
- New drug approvals in oncology (2020) (18)
- Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease. (2016) (18)
- Sequential interleukin 3 and granulocyte‐macrophage–colony stimulating factor therapy in patients with bone marrow failure with long‐term follow‐up of responses (2003) (18)
- Outcomes of Phase II Clinical Trials with Single-Agent Therapies in Advanced/Metastatic Non-Small Cell Lung Cancer Published between 2000 and 2009 (2012) (18)
- Analysis of the effects of tumor necrosis factor inhibitors on human hematopoiesis (1993) (18)
- First in human phase I study of MK-2461, a small molecule inhibitor of c-Met, for patients with advanced solid tumors (2008) (18)
- Pertuzumab plus trastuzumab for HER2-positive metastatic urothelial cancer (mUC): Preliminary data from MyPathway. (2017) (18)
- Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients (2020) (18)
- Autocrine lymphotoxin production in Epstein–Barr virus-immortalized B cells: induction via NF-κB activation mediated by EBV-derived latent membrane protein 1 (2003) (18)
- The Mutational Landscape of Gastrointestinal Malignancies as Reflected by Circulating Tumor DNA (2017) (18)
- Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy. (2022) (18)
- A phase I study of recombinant interferon-beta in patients with advanced malignant disease. (1999) (18)
- Dual inhibition of IGFR and mTOR pathways. (2010) (17)
- Phase I trial of combination sorafenib and tipifarnib: The experience in advanced differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC). (2010) (17)
- Malignancy-associated tripe palms. (1992) (17)
- Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress? (2019) (17)
- Targeting G1/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor-based regimens. (2021) (17)
- VEGF and dual-EGFR inhibition in colorectal cancer (2015) (17)
- Not Just a BRCA1-Associated Protein (2020) (17)
- Multiple gene aberrations and breast cancer: lessons from super-responders (2015) (17)
- Revisiting Clinical Trials Using EGFR Inhibitor-Based Regimens in Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Analysis of an MD Anderson Cancer Center Phase I Population (2013) (17)
- Cancer of Unknown Primary in the Molecular Era. (2021) (17)
- Cytoplasmic and nuclear localization of the 130 and 160 kDa Bcr proteins (2000) (17)
- Curcumin and pancreatic cancer: Phase II clinical trial experience (2007) (17)
- Patients with Advanced Head and Neck Cancers Have Similar Progression-Free Survival on Phase I Trials and Their Last Food and Drug Administration–Approved Treatment (2010) (17)
- Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study (2021) (17)
- A phase I study of ISIS 481464 (AZD9150), a first-in-human, first-in-class, antisense oligonucleotide inhibitor of STAT3, in patients with advanced cancers. (2013) (17)
- Molecular analysis of chromosome 22 breakpoints in adult Philadelphia‐positive acute lymphoblastic leukaemia (1987) (17)
- Circulating Tumor Cells: From the Laboratory to the Cancer Clinic (2020) (17)
- A Comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors (2012) (16)
- IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers (2020) (16)
- Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a Phase I Clinic: The M. D. Anderson Cancer Center experience (2008) (16)
- Preliminary Results from an Ongoing Phase 1/2 Study of INCB057643, a Bromodomain and Extraterminal (BET) Protein Inhibitor, in Patients (pts) with Advanced Malignancies (2017) (16)
- Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics (2021) (16)
- Chronic myelogenous leukemia in chronic phase (2001) (16)
- Treatment of cyclic neutropenia with very low doses of GM-CSF. (1991) (16)
- Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement (2010) (16)
- Effect of sampling frequency on perfusion values in perfusion CT of lung tumors. (2013) (16)
- The National Clinical Trials Network: Conducting Successful Clinical Trials of New Therapies for Rare Cancers. (2015) (16)
- Clinical outcomes of patients with breast cancer in a phase I clinic: the M. D. Anderson cancer center experience. (2010) (16)
- Unique Genomic Landscape of High-Grade Neuroendocrine Cervical Carcinoma: Implications for Rethinking Current Treatment Paradigms (2020) (16)
- PIK 3 CA Mutations in Advanced Cancers : Characteristics and Outcomes (2013) (16)
- Cytokines and their antagonists in myeloid disorders. (1995) (16)
- Liquid biopsy: current technology and clinical applications (2022) (16)
- BRAF V600 mutant colorectal cancer (CRC) expansion cohort from the phase I/II clinical trial of BRAF inhibitor dabrafenib (GSK2118436) plus MEK inhibitor trametinib (GSK1120212). (2012) (16)
- Temporal and spatial effects and survival outcomes associated with concordance between tissue and blood KRAS alterations in the pan‐cancer setting (2019) (16)
- Phase I trial with a novel oral NF-{kappa}B/STAT3 inhibitor RTA 402 in patients with solid tumors and lymphoid malignancies (2008) (16)
- Autocrine cell suicide in a Burkitt lymphoma cell line (Daudi) induced by interferon alpha: involvement of tumor necrosis factor as ligand for the CD95 receptor. (2001) (16)
- NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies. (2014) (16)
- SMARCA4: Implications of an Altered Chromatin-Remodeling Gene for Cancer Development and Therapy (2021) (16)
- Systematic analysis of early phase clinical studies for patients with breast cancer: Inclusion of patients with brain metastasis. (2017) (16)
- First-in-human phase I study of the novel structure proteasome inhibitor NPI-0052. (2016) (15)
- Phase I dose-escalation study of E7080, a selective tyrosine kinase inhibitor, administered orally to patients with solid tumors. (2010) (15)
- Results of a phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket directed SRC inhibitor, in patients with advanced malignancies. (2009) (15)
- Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial (2018) (15)
- A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers (2019) (15)
- Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology (2015) (15)
- Comparison of in vivo and in vitro effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with acute myeloid leukemia. (1992) (15)
- The inverted pyramid of biomarker-driven trials (2011) (15)
- Precision medicine: Clinical outcomes including long-term survival according to the pathway targeted and treatment period–The IMPACT study. (2018) (15)
- The importance of greater speed in drug development for advanced malignancies (2018) (15)
- Interferon alpha in the therapy of CML (1991) (15)
- What is the contribution of molecular studies to the diagnosis of BCR-ABL-positive disease in adult acute leukemia? (1994) (15)
- Therapy of T Cell Lymphomas with Pentostatin (2001) (14)
- Necrotizing vasculitis at granulocyte-macrophage-colony-stimulating factor injection sites. (1990) (14)
- Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer (2014) (14)
- Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes. (2013) (14)
- Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma. (2015) (14)
- Radiation Therapy Combined With Checkpoint Blockade Immunotherapy for Metastatic Undifferentiated Pleomorphic Sarcoma of the Maxillary Sinus With a Complete Response (2018) (14)
- Adjuvant interferon in high-risk melanoma: end of the era? (2010) (14)
- PIK3CA, KRAS, and BRAF mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. (2010) (14)
- Effect of Dual Vascular Input Functions on CT Perfusion Parameter Values and Reproducibility in Liver Tumors and Normal Liver (2012) (14)
- Hairy cell leukaemia: review of treatment (1991) (14)
- Recent advances in the therapy of chronic myelogenous leukemia. (1988) (14)
- Thrombopoietin stimulates myelodysplastic syndrome granulocyte-macrophage and erythroid progenitor proliferation. (1998) (14)
- Expression of estrogen and progesterone receptors across human malignancies: new therapeutic opportunities (2015) (14)
- Response of lymphangioleiomyomatosis to a mammalian target of rapamycin inhibitor (temsirolimus) -based treatment. (2011) (14)
- Phase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer Center experience. (2010) (14)
- Role of interleukin-1 inhibitory molecules in therapy of acute and chronic myelogenous leukemia. (1993) (14)
- A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609) (2021) (14)
- Phase I trial of PX-866, a novel phosphoinositide-3-kinase (PI-3K) inhibitor. (2009) (14)
- Early-stage multi-cancer detection using an extracellular vesicle protein-based blood test (2022) (14)
- Exploratory study of hepatic arterial infusion oxaliplatin with systemic 5-fluorouracil/bevacizumab in patients with refractory solid tumor and extensive liver metastases. (2010) (13)
- Targeted therapy for advanced solid tumors based on molecular profiles: Early results from MyPathway, an open-label, phase IIa umbrella basket study. (2016) (13)
- Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy (2015) (13)
- Heterogeneity in lineage derivation of Philadelphia-positive acute lymphoblastic leukemia expressing p190BCR-ABL or p210BCR-ABL: determination by analysis of individual colonies with the polymerase chain reaction. (1993) (13)
- Interleukin-6: biologic properties and role in lymphoproliferative disorders. (1996) (13)
- Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver (2013) (13)
- Kinetic monitoring of EGFR T790M in urinary circulating tumor DNA to predict radiographic progression and response in patients with metastatic lung adenocarcinoma. (2015) (13)
- U.S. Food and Drug Administration Inspections of Clinical Investigators: Overview of Results from 1977 to 2009 (2014) (13)
- Phase I pilot study of the safety and tolerability of olanzapine (OZA) for the treatment of cachexia in patients with advanced cancer (2008) (13)
- Comparative genomic analysis of intrahepatic cholangiocarcinoma: biopsy type, ancestry and testing patterns. (2021) (13)
- Phase I Study Using Alternate Week Administration of the Farnesyl Transferase Inhibitor R115777 (Zarnestra™) in Patients with Myelodysplastic Syndrome. (2004) (13)
- Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies (2019) (13)
- Phase I study of tipifarnib and sorafenib in patients with biopsiable advanced cancer (NCI protocol 7156) (2008) (13)
- Pharmacodynamic and efficacy analysis of the BRAF inhibitor dabrafenib (GSK436) in combination with the MEK inhibitor trametinib (GSK212) in patients with BRAFV600 mutant colorectal cancer (CRC). (2013) (13)
- Chronic myelogenous leukemia--progress at the M. D. Anderson Cancer Center over the past two decades and future directions: first Emil J Freireich Award Lecture. (1997) (13)
- Transient acantholytic dermatosis after treatment with 2-chlorodeoxyadenosine. (1997) (13)
- Minimal residual disease in hematologic disorders. (1999) (13)
- A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours (2014) (13)
- A cancer trial scandal and its regulatory backlash (2014) (13)
- Impact of p210Bcr-Abl on Ultraviolet C Wavelength-induced DNA Damage and Repair (2003) (13)
- A tale of two histiocytic disorders. (2013) (13)
- Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors (2015) (12)
- Targeted therapy for genetic cancer syndromes: Von Hippel-Lindau disease, Cowden syndrome, and Proteus syndrome. (2015) (12)
- Cancer research in the United States: A critical review of current status and proposal for alternative models (2018) (12)
- Missing the target in cancer therapy (2021) (12)
- Cyclin Pathway Genomic Alterations Across 190,247 Solid Tumors: Leveraging Large‐Scale Data to Inform Therapeutic Directions (2020) (12)
- STK11 alterations in the pan-cancer setting: prognostic and therapeutic implications. (2021) (12)
- A phase I study of bevacizumab in combination with sunitinib, sorafenib, and erlotinib plus cetuximab, and trastuzumab plus lapatinib. (2010) (12)
- Efficacy, safety, biomarkers, and phase II dose modeling in a phase I trial of the oral selective c-Met inhibitor tepotinib (MSC2156119J). (2015) (12)
- The mutational landscape of gastrointestinal malignancies as reflected by circulating tumor DNA. (2017) (12)
- Core Clinical Data Elements for Cancer Genomic Repositories: A Multi-stakeholder Consensus (2017) (12)
- Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience. (2012) (12)
- Establishment of Patient-Derived Succinate Dehydrogenase–Deficient Gastrointestinal Stromal Tumor Models for Predicting Therapeutic Response (2021) (12)
- PI3K Kinase Inhibitor GSK2126458 (GSK458): Clinical Activity in Select Patient (PT) Populations Defined by Predictive Markers (STUDY P3K112826) (2012) (12)
- 2-chlorodeoxyadenosine-associated transient acantholytic dermatosis in hairy cell leukemia patients. (1999) (12)
- Pharmacokinetics (PK) and pharmacodynamics (PD) of RG7112, an oral murine double minute 2 (MDM2) antagonist, in patients with leukemias and solid tumors. (2011) (12)
- The "shield sign" in two men with metastatic salivary duct carcinoma to the skin: cutaneous metastases presenting as carcinoma hemorrhagiectoides. (2012) (12)
- A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. (2020) (12)
- Compliance in early-phase cancer clinical trials research. (2013) (12)
- The M.D. Anderson Cancer Center experience with interferon-alpha therapy in chronic myelogenous leukaemia. (1997) (12)
- First-in-human study of AMG 386, a selective angiopoietin1/2-neutralizing peptibody, in adult patients with advanced solid tumors (2007) (12)
- Phase II evaluation of PALA in patients with refractory metastatic sarcomas (1984) (12)
- Concordance between TP53 alterations in blood and tissue: impact of time interval, biopsy site, cancer type and circulating tumor DNA burden (2020) (11)
- Abstract CT039: A Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) S1609: The neuroendocrine cohort (2019) (11)
- The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab. (2015) (11)
- Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy (2015) (11)
- Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples (2014) (11)
- Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds (2020) (11)
- PTEN assessment and PI3K/mTOR inhibitors: Importance of simultaneous assessment of MAPK pathway aberrations. (2012) (11)
- Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic. (2011) (11)
- Clinical pharmacokinetics (PK) of EZN-2208, a novel anticancer agent, in patients (pts) with advanced malignancies: A phase I, first-in-human, dose-escalation study (2008) (11)
- ANG1005: Results of a phase I study in patients with advanced solid tumors and brain metastases. (2010) (11)
- A first-in-human phase I trial of PBI-05204 (oleandrin), an inhibitor of Akt, FGF-2, NF-Kb, and p70S6K in advanced solid tumor patients. (2009) (11)
- Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response. (2014) (11)
- Health policy: The right to try is embodied in the right to die (2016) (11)
- Posterior reversible encephalopathy syndrome: more than meets the eye. (2013) (11)
- Characteristics and survival of patients with advanced cancer and p53 mutations (2014) (11)
- Interim results of a phase I trial with a novel orally administered synthetic triterpenoid RTA 402 (CDDO-Me) in patients with solid tumors and lymphoid malignancies (2007) (11)
- Clinical trial design in the era of precision medicine (2022) (11)
- Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF‐mutated melanoma and other advanced malignancies (2018) (11)
- A first-in-human phase I study of VGX-100, a selective anti-VEGF-C antibody, alone and in combination with bevacizumab in patients with advanced solid tumors. (2014) (11)
- JAK1 Genomic Alteration Associated With Exceptional Response to Siltuximab in Cutaneous Castleman Disease (2017) (11)
- Results of the first-in-human phase I trial assessing MSC2156119J (EMD 1214063), an oral selective c-Met inhibitor, in patients (pts) with advanced solid tumors. (2014) (11)
- Selpercatinib Aimed at RET-Altered Cancers. (2020) (10)
- Interleukin-1 and its inhibitors: implications for disease biology and therapy. (1995) (10)
- Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma (2020) (10)
- Impact of p210(Bcr-Abl) on ultraviolet C wavelength-induced DNA damage and repair. (2003) (10)
- KRAS‐Mutated, Estrogen Receptor‐Positive Low‐Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery (2021) (10)
- Hepatic arterial infusion therapy in advanced cancer and liver-predominant disease: the MD Anderson Experience. (2013) (10)
- Metastasis–An alternative hypothesis (2005) (10)
- HHV-8-Negative, Idiopathic Multicentric Castleman Disease (iMCD): A Description of Clinical Features and Therapeutic Options through a Systematic Literature Review (2014) (10)
- SWOG 1609 (DART): A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors. (2019) (10)
- Pentostatin (Nipent) in T-cell lymphomas. (2000) (10)
- Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials (2015) (10)
- Intensive combination chemotherapy and interferons in the management of chronic myelogenous leukemia. (1987) (10)
- Phase I/II study of weekly paclitaxel with or without MLN8237 (alisertib), an investigational aurora A kinase inhibitor, in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (OC), or breast cancer (BrC): Phase I results. (2012) (10)
- Synergy Between VEGF/VEGFR Inhibitors and Chemotherapy Agents in the Phase I Clinic (2014) (10)
- 151 AMG 706 first in human, open-label, dose-finding study evaluating the safety and pharmacokinetics (PK) in subjects with advanced solid tumors (2004) (10)
- Total Number of Alterations in Liquid Biopsies Is an Independent Predictor of Survival in Patients With Advanced Cancers (2020) (10)
- Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs. (2012) (10)
- Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial (2020) (10)
- Personalized, molecularly matched combination therapies for treatment-na. (2017) (10)
- Phase I study of tipifarnib and sorafenib in patients with biopsiable advanced cancers (NCI protocol 7156 supported by NCI grant UO1 CA062461) (2007) (10)
- Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies (2007) (10)
- HER2-Amplified Salivary Duct Carcinoma: Regression with Dual HER2 Inhibition and Anti-VEGF Combination Treatment (2014) (9)
- MyPathway HER2 basket study: Pertuzumab (P) + trastuzumab (H) treatment of a large, tissue-agnostic cohort of patients with HER2-positive advanced solid tumors. (2021) (9)
- Synergistic antiproliferative effect of interferon alpha and azidothymidine in chronic myelogenous leukemia. (1991) (9)
- Are Cancer Patients at Higher Risk of Death With COVID-19? (2020) (9)
- Actionability and precision oncology (2015) (9)
- Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities (2017) (9)
- Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors (2014) (9)
- Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors (2013) (9)
- Juice plus or toxicity plus. (2010) (9)
- An Open-Label, Phase 2, Multicenter Study Of The Safety Of Long-Term Treatment With Siltuximab (an Anti-Interleukin-6 Monoclonal Antibody) In Patients With Multicentric Castleman’s Disease (2013) (9)
- Purine analogues in advanced T-cell lymphoid malignancies. (2006) (9)
- 405 POSTER A phase I dose-escalation study of the safety and pharmacokinetics of a XL184, a VEGFR and Met kinase inhibitor, administered orally to subjects with advanced malignancies (2006) (9)
- Phase I study of a combination of recombinant tumor necrosis factor-alpha and recombinant interferon-gamma in cancer patients. (1989) (9)
- Targeting fusions for improved outcomes in oncology treatment (2019) (9)
- Activity of the mTOR inhibitor sirolimus and HDAC inhibitor vorinostat in heavily pretreated refractory Hodgkin lymphoma patients. (2014) (9)
- Prospective study comparing outcomes in patients with advanced malignancies on molecular alteration-matched versus non-matched therapy. (2015) (9)
- Therapy of chronic myelogenous leukemia with interferon. (1989) (9)
- Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer (2015) (9)
- Autoantibodies to Abl and Bcr proteins (2000) (9)
- Therapeutic Implications of Epidermal Growth Factor Receptor (EGFR) in the Treatment of Metastatic Gastric/GEJ Cancer (2020) (9)
- High prevalence of clonal hematopoiesis‐type genomic abnormalities in cell‐free DNA in invasive gliomas after treatment (2021) (9)
- A phase I study of q3W R1507, a human monoclonal antibody IGF-1R (insulin-like growth factor receptor) antagonist in patients with advanced solid tumors (2007) (9)
- Prognostic Utility of Pre- and Postoperative Circulating Tumor DNA Liquid Biopsies in Patients with Peritoneal Metastases (2020) (9)
- CNTO 328, a Monoclonal Antibody to Interleukin-6, Is Active as a Single Agent in Castleman’s Disease: Preliminary Results of a Phase I Study. (2008) (9)
- Merkel Cell Carcinoma with a Suppressor of Fused (SUFU) Mutation: Case Report and Potential Therapeutic Implications (2015) (8)
- Remembering the forgotten child: the role of immune checkpoint inhibition in patients with human immunod eficiency virus and cancer (2019) (8)
- Paraneoplastic erythromelalgia. (1993) (8)
- Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome. (2014) (8)
- rhIL-11 for the prevention of dose-limiting chemotherapy-induced thrombocytopenia. (2000) (8)
- Immune profiling and immunotherapeutic targets in pancreatic cancer (2021) (8)
- New therapeutic approaches to overcoming resistant EGFR exon 20 alterations. (2020) (8)
- Anakinra-responsive lichen planus in a woman with Erdheim-Chester disease: a therapeutic enigma. (2014) (8)
- A phase I study of niraparib in combination with temozolomide (TMZ) in patients with advanced cancer. (2014) (8)
- Modifying the Clinical Research Infrastructure at a Dedicated Clinical Trials Unit: Assessment of Trial Development, Activation, and Participant Accrual (2016) (8)
- Outcomes of patients ≥65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER (2017) (8)
- RAF Inhibitor Dabrafenib (GSK2118436) is Active in Melanoma Brain Metastases, Multiple BRAF Genotypes and Diverse Cancers (2014) (8)
- Bringing Blood-Based Molecular Testing to the Clinic (2016) (8)
- Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities. (2017) (8)
- Cixutumumab combined with temsirolimus in patients with refractory Ewing's sarcoma. (2011) (8)
- Leukemia inhibitory factor in long-term adherent layer cultures: increased levels of bioactive protein in leukemia and modulation by IL-4, IL-1 beta, and TNF-alpha. (1994) (8)
- A Phase I/II Study of the Oral mTOR Inhibitor RAD001 in Patients with Advanced Hematologic Malignancies (2004) (8)
- Phosphatase and tensin homologue (PTEN) loss and response to phase I trials targeting PI3K/AKT/mTOR pathway in patients with advanced cancer. (2010) (8)
- Therapy of chronic myelogenous leukaemia with interferons. (1989) (8)
- Decitabine impact on the endocytosis regulator RhoA, the folate carriers RFC1 and FOLR1, and the glucose transporter GLUT4 in human tumors (2014) (8)
- Herpes simplex virus infections and cimetidine therapy. (1988) (8)
- Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients (2020) (8)
- P1-17-10: Cabozantinib (XL184) in Patients with Metastatic Breast Cancer: Results from a Phase 2 Randomized Discontinuation Trial. (2011) (8)
- Langerhans cell histiocytosis of the thyroid (2006) (7)
- Spotlight on Clinical Response Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo 2 L / TRAIL ( Dulanermin ) , a Dual Proapoptotic Receptor ( DR 4 / DR 5 ) Agonist (2012) (7)
- Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. (2013) (7)
- Abstract A168: First results from a phase I trial of AZD8055, a dual mTORC1 and mTORC2 inhibitor. (2011) (7)
- WINTHER: An international WIN Consortium precision medicine trial using genomic and transcriptomic analysis in patients with advanced malignancies. (2018) (7)
- Combination of 5-azacytidine (5-AZA) and valproic acid (VPA) in advanced solid cancers: A phase I study (2007) (7)
- An avatar for precision cancer therapy (2018) (7)
- Impact of precision medicine in refractory malignancies: A meta-analysis of 13,203 patients in phase I clinical trials. (2016) (7)
- Abstract C216: Phase 1, first‐in‐human, dose‐escalation study of EZN‐2208, a novel anticancer agent, in patients (pts) with advanced malignancies (2009) (7)
- Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors. (2015) (7)
- Effect of duration of scan acquisition on CT perfusion parameter values in primary and metastatic tumors in the lung. (2013) (7)
- Lessons From the Development of the Immune Checkpoint Inhibitors in Oncology (2018) (7)
- Moving Beyond 3+3: The Future of Clinical Trial Design. (2021) (7)
- Phase I study of the novel proteasome inhibitor NPI-0052 in patients with lymphoma and solid tumors (2008) (7)
- 795 A multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) (2020) (7)
- Abstract A211: A phase I study of MABp1, a first-in-human, first-true human monoclonal antibody against the IL-1 in patients with advanced cancers. (2011) (7)
- Interleukin-1 increases expression of the LYT-10 (NFkappaB2) proto-oncogene/transcription factor in renal cell carcinoma lines. (1998) (7)
- Schnitzler syndrome associated with MYD88 L265P mutation (2019) (7)
- Classification and Diagnosis of Erythromelalgia (1995) (7)
- Basal Cell Carcinoma: Management of Advanced or Metastatic Cancer with Checkpoint Inhibitors and Concurrent Paradoxical Development of New Superficial Tumors. (2020) (7)
- Interferons: Basic Principles and Clinical Applications (1993) (7)
- Interleukin-1 and its inhibitors: a biologic and therapeutic model for the role of growth regulatory factors in leukemias. (1995) (7)
- Factors related to biopsy willingness in patients with advanced cancer in a phase 1 clinic for molecularly targeted therapy (2013) (7)
- Survival Implications of the Relationship between Tissue versus Circulating Tumor DNA TP53 Mutations—A Perspective from a Real-World Precision Medicine Cohort (2020) (7)
- Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver (2015) (7)
- Phase 1 clinical trials in 83 patients with pancreatic cancer (2011) (7)
- Phase I dose-escalation study of the investigational Aurora A kinase (AAK) inhibitor MLN8237 as an enteric-coated tablet (ECT) formulation in patients with nonhematologic malignancies. (2011) (7)
- Repurposing Interleukin-6 Inhibitors to Combat COVID-19. (2020) (7)
- Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience. (2012) (7)
- Outcomes of patients with metastatic cervical cancer in a phase I clinical trials program. (2014) (7)
- The coming decade in precision oncology: six riddles (2022) (7)
- First-in-Human Phase 1 Dose Escalation Study of NPI-0052, a Novel Proteasome Inhibitor, in Patients with Lymphoma and Solid Tumor (2008) (6)
- Merkel cell polyomavirus and human papilloma virus in proliferative skin lesions arising in patients treated with BRAF inhibitors (2016) (6)
- Molecular imaging of Bcr-Abl phosphokinase in a xenograft model (2009) (6)
- Phase-1 trial of ZIO-101, a novel organic arsenic in patients with advanced cancers. (2006) (6)
- Interleukin 4 alters human bone marrow stroma and modulates its interaction with hematopoietic progenitors (1994) (6)
- The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments (2020) (6)
- 86MO Personalized molecularly matched therapies for carcinomas of unknown primary is associated with improved outcomes (2020) (6)
- Serial changes in liquid biopsy-derived variant allele frequency predict immune checkpoint inhibitor responsiveness in the pan-cancer setting (2022) (6)
- Pertuzumab and trastuzumab for HER2-amplified metastatic colorectal cancer: an updated report from MyPathway, a multicentre, open-label, phase 2a multiple basket study (2019) (6)
- A phase I/II study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress. (2021) (6)
- Association of differential expression of immunoregulatory molecules and presence of targetable mutations may inform rational design of clinical trials (2022) (6)
- Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer (2021) (6)
- Future clinical implications for farnesyltransferase inhibitors in hematologic malignancies. (2002) (6)
- Population Pharmacokinetic and Pharmacodynamic Modeling of an Anti–Interleukin-6 Chimeric Monoclonal Antibody, Siltuximab (CNTO 328), in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease (2012) (6)
- Balancing clinical evidence in the context of a pandemic (2021) (6)
- Real-World Toxicity Experience with BRAF/MEK Inhibitors in Patients with Erdheim-Chester Disease. (2019) (6)
- Two phase 1 studies of MPC-6827, a novel vascular disrupting agent (VDA), in patients with advanced solid tumors and CNS metastases (2007) (6)
- Cutaneous Castleman disease (2012) (6)
- Real‐World Toxicity Experience with BRAF/MEK Inhibitors in Patients with Erdheim‐Chester Disease (2019) (6)
- Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials (2013) (6)
- 608 Phase I Dose-escalation Trial of a Selective Oral MEK1/2 Inhibitor, Pimasertib (MSC1936369B), Combined with an mTOR Inhibitor, Temsirolimus, in Patients with Advanced Solid Tumors (2012) (6)
- Interruption of endogenous growth regulatory networks: A novel approach to inhibition of leukaemia cell proliferation (1993) (6)
- Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients with Advanced Malignancies: A Phase I Clinical Trial (2011) (6)
- Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers (2018) (6)
- Alternate Week Administration of the Farnesyltransferase Inhibitor Tipifarnib (ZARNESTRA®, R115777) in Patients with Myelodysplastic Syndrome: Results of a Phase 1 Study. (2005) (6)
- Cutaneous T Cell Lymphoma: Responses in Phase 1 Trial of Combination Therapy with Liposomal Doxorubicin, Bortezomib, and Gemcitabine. (2006) (6)
- Targeted therapy for non-small cell lung cancer (NSCLC) with HER2, BRAF, or hedgehog alterations: Interim data from MyPathway. (2017) (6)
- Phase I study of MGCD265 administered intermittently to patients with advanced malignancies (Study 265-102). (2009) (5)
- Dodging a dogma: is treating beyond progression beneficial? (2013) (5)
- Multi-omic analysis in carcinoma of unknown primary (CUP): therapeutic impact of knowing the unknown. (2022) (5)
- Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: The university of Texas MD Anderson cancer center experience (2014) (5)
- Molecular imaging of gefitinib activity in an epidermal growth factor receptor (EGFR)-bearing xenograft model (2009) (5)
- Siltuximab Reverses Muscle Wasting In Patients With Multicentric Castleman’s Disease (2013) (5)
- Relationship between tumor mutational burden and maximum standardized uptake value in 2-[18F]FDG PET (positron emission tomography) scan in cancer patients (2020) (5)
- Phase I study of low-dose hypomethylating agent azacitidine (5-AC) combined with the histone deacetylase inhibitor valproic acid (VPA) in patients with advanced cancers. (2006) (5)
- Phase 1 Clinical Trial of a Novel Proteasome Inhibitor (NPI-0052) in Patients with Lymphomas and Solid Tumors. (2007) (5)
- Novel phase I study combining G1 phase, S phase, and G2/M phase cell cycle inhibitors in patients with advanced malignancies (2015) (5)
- Phase I trial of sorafenib, bevacizumab, and temsirolimus in advanced solid tumors. (2013) (5)
- Refractory Hodgkin lymphoma responds to pentostatin (2′-deoxycoformycin) (2006) (5)
- Targeted Therapy in Translational Cancer Research (2015) (5)
- Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown Primary (2021) (5)
- Genomics of Immunotherapy-Associated Hyperprogressors—Response (2017) (5)
- 214 THE CHANGING FACE OF PHASE I CANCER CLINICAL TRIALS: NEW CHALLENGES IN STUDY REQUIREMENTS. (2007) (5)
- Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy (2022) (5)
- Attrition of Patients on a Precision Oncology Trial: Analysis of the I‐PREDICT Experience (2020) (5)
- Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals. (2019) (5)
- Targeted therapy for hereditary cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndrome. (2014) (5)
- TP53 mutations and number of alterations correlate with maximum standardized uptake value (SUVmax) determined by positron emission tomography/computed tomography (PET/CT) [18F] fluorodeoxyglucose (18F-FDG PET) (2018) (5)
- Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer (2011) (5)
- Activity of the MEK Inhibitor Trametinib (GSK1120212) in Advanced Melanoma in a Phase I, Dose-escalation Trial (2014) (5)
- A Phase I Study of CNTO 328, An Anti-Interleukin-6 Monoclonal Antibody in Patients with B-Cell Non-Hodgkin’s Lymphoma, Multiple Myeloma, or Castleman’s Disease. (2008) (5)
- Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation (2013) (5)
- Evaluation of pharmacokinetics (PK) and pharmacodynamics (PD) of patupilone and warfarin in patients (pts) with advanced solid tumors: An open-label, phase I study (2008) (5)
- Targeted therapy for advanced salivary cancer with HER2 or hedgehog alterations: Interim data from MyPathway. (2017) (5)
- Abstract LB-227: Preclinical pharmacology and clinical efficacy of AZD9150 (ISIS-STAT3Rx), a potent next-generation antisense oligonucleotide inhibitor of STAT3 (2014) (5)
- Granulocyte-macrophage colony-stimulating factor and interleukin-3 in combination: A potent and consistent myelodysplastic syndrome bone marrow stimulant in vitro (1991) (5)
- Snapshot: Trial Types in Precision Medicine (2020) (5)
- Castleman’s disease and sarcoidosis, a rare association resulting in a “mixed” response: a case report (2015) (5)
- Phase I study of the safety and efficacy of atiprimod, a novel azaspirine, for patients with advanced cancer. (2006) (5)
- An adaptive randomized discontinuation trial of XL184 (BMS-907351) in patients (pts) with advanced solid tumors. (2010) (5)
- Machine learning model to predict oncologic outcomes for drugs in randomized clinical trials (2020) (5)
- Accelerated approvals hit the target in precision oncology (2022) (5)
- Could Antitumor Activity of Curcumin in Patients Be due to Its Metabolites? A Response (2009) (5)
- Clinical, pharmacokinetic (PK), pharmacodynamic findings in a phase I trial of weekly (wkly) intravenous AZD4877 in patients with refractory solid tumors (2008) (5)
- Assessing CAR T-cell therapy response using genome-wide sequencing of cell-free DNA in patients with B-cell lymphomas. (2021) (5)
- Tumor mutational burden is not predictive of cytotoxic chemotherapy response (2020) (5)
- Benign rheumatoid nodules in a woman with chronic lymphocytic leukaemia and borderline lepromatous leprosy. (1993) (5)
- Treated with PI 3 K / AKT / mTOR Axis Inhibitors Mutations in Patients with Advanced Cancers (2011) (4)
- Abstract B247: A phase 1 safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients with advanced solid tumors (2009) (4)
- Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. (2015) (4)
- Increased cancer antigen 27.29 (CA27.29) level in patients with mycosis fungoides. (2008) (4)
- Phase I, multicenter trial of CNTO 328, an anti-interleukin(IL)-6 monoclonal antibody (mAb) in subjects with selected hematologic malignancies. (2006) (4)
- Phase I dose-escalation study of sodium stibogluconate (SSG), a protein tyrosine phosphatase inhibitor, combined with interferon-alfa for patients with solid tumors (2008) (4)
- Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors (2018) (4)
- The FGFR landscape in cancer: An analysis of 4,869 cases. (2014) (4)
- Evaluation of CNS and peripheral antitumor activity of ANG1005 in patients with brain metastases from breast tumors and other advanced solid tumors. (2014) (4)
- 246 Aberrations in PIK3CA, PTEN, and MAPK (KRAS, NRAS, BRAF) in 1,656 Patients and Experience with Early-phase Protocols with PI3K/AKT/mTOR Inhibitors (2012) (4)
- Cutaneous perivascular epithelioid cell tumor (PEComa): case report and world literature review of clinical and molecular characteristics. (2022) (4)
- Turmeric and green tea: a recipe for B-Chronic Lymphocytic Leukemia (2009) (4)
- Risks and Benefits of Phase 1 Oncology Trials, Revisited (2008) (4)
- Polycystic ovary syndrome in men. (2017) (4)
- Landscape of Cyclin Pathway Genomic Alterations Across 5,356 Prostate Cancers: Implications for Targeted Therapeutics (2021) (4)
- Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study (2019) (4)
- 371 Phase 2 randomized discontinuation trial (RDT) of XL184 in patients (pts) with advanced solid tumors (2010) (4)
- The Impact of COVID-19 on Cancer Clinical Trials Conducted by NCI-Designated Comprehensive Cancer Centers. (2020) (4)
- Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome (2022) (4)
- Anticoagulation-induced severe bleeding in a patient receiving bevacizumab therapy (2011) (4)
- Promoting Precision Cancer Medicine through a Community-Driven Knowledgebase (2014) (4)
- Hematopoietic growth factors in bone marrow failure states (2003) (4)
- Phase I open-labeled trial of gemcitabine and dasatinib in advanced solid tumors (2008) (4)
- Treatment of chronic myelogenous leukemia as a paradigm for solid tumors: how targeted agents in newly diagnosed disease transformed outcomes. (2012) (4)
- Insulin-like growth factor 1 receptor (IGF-1R) inhibitor: another arrow in the quiver – Will it hit the moving target? (2011) (4)
- Real-World Data From a Molecular Tumor Board: Improved Outcomes in Breast and Gynecologic Cancers Patients With Precision Medicine (2022) (4)
- Phase 2 Study of Cabozantinib (XL184) in a Cohort of Patients With Castration-Resistant Prostate Cancer (CRPC) and Measurable Soft Tissue Disease (2011) (4)
- Phase I/II, two-part, open-label, multiple-dose, dose-escalation study of siltuximab in patients with solid tumors (2012) (4)
- Erratum to "Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies" [Oncotarget., 6 (2015) 12809-12821] (2015) (4)
- Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer. (2014) (4)
- Novel somatic alterations in unicentric and idiopathic multicentric Castleman disease (2021) (4)
- Phase I study of oral selective c-Met inhibitor EMD 1214063 in pts with advanced solid tumors. (2013) (4)
- Alpha interferon dose-dependent suppression of secondary clones in a patient with Philadelphia-positive chronic myelogenous leukemia. (1990) (3)
- BRAF mutation as a novel driver of eosinophilic cystitis (2017) (3)
- MEK Inhibition with Trametinib in Patients with Non-Langerhans Cell Histiocytosis (2019) (3)
- Improving the institutional submission and approval process for clinical research protocols in oncology. (2007) (3)
- Genome-wide Sequencing of Cell-free DNA Enables Detection of Copy-number Alterations in Patients with Cancer Where Tissue Biopsy is Not Feasible (2021) (3)
- Precision Medicine Clinical Trials: Successes and Disappointments, Challenges and Opportunities – Lessons Learnt (2018) (3)
- JAK2 V617F mutation in plasma cell-free DNA preceding clinically overt myelofibrosis: Implications for early diagnosis (2018) (3)
- Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals (2019) (3)
- Studies in target-based treatment (2007) (3)
- Screening for PIK3CA mutations, PTEN loss, and RAS/RAF mutations in early-phase protocols with PI3K/mTOR pathway inhibitors. (2011) (3)
- L04.04 * Winther: a study to select rational therapeutics based on the analysis of tumor and matched normal tissue biopsies in subjects with advanced malignancies (2013) (3)
- p53 mutations in advanced cancers: Clinical characteristics and outcomes in a phase I setting. (2012) (3)
- Alpha-T: An innovative decentralized (home-based) phase 2 trial of alectinib in ALK-positive (ALK+) solid tumors in a histology-agnostic setting. (2021) (3)
- Intra-patient stability of tumor mutational burden from tissue biopsies at different time points in advanced cancers (2021) (3)
- Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience. (2012) (3)
- BRAF V600E/V600K Mutations versus Nonstandard Alterations: Prognostic Implications and Therapeutic Outcomes (2021) (3)
- A phase I study determining the safety and tolerability of combination therapy with pazopanib, a VEGFR/PDGFR/raf inhibitor, and GSK1120212, a MEK inhibitor, in advanced solid tumors enriched with patients with advanced differentiated thyroid cancer. (2012) (3)
- Advanced basal cell cancer: concise review of molecular characteristics and novel targeted and immune therapeutics. (2019) (3)
- Assessment of clinical activity of E7080, a multitargeted kinase inhibitor, in patients with advanced melanoma treated in two phase I trials. (2011) (3)
- Chromatin remodeling (SWI/SNF) complexes, cancer, and response to immunotherapy (2022) (3)
- CNTO 328, an Anti-Interleukin (IL)-6 Monoclonal Antibody (mAb) - Preliminary Results of Subjects with Castleman’s Disease from a Phase 1 Study in Selected Hematological Malignancies. (2006) (3)
- RAS Inhibitors in Hematologic Cancers: Biologic Considerations and Clinical Applications (2004) (3)
- Retreatment after Secondary Resistance or Mixed Response: A Pilot Study (2013) (3)
- syndrome in men. (2019) (3)
- Therapeutic implications of cancer gene amplifications without mRNA overexpression: silence may not be golden (2021) (3)
- Phase I study combining an IGFR inhibitor (IMC-A12) and an mTOR inhibitor (temsirolimus) in patients with solid tumors or lymphoma. (2016) (3)
- Warning signal: unaware of an in absentia conviction, South African cancer specialist jailed on return to the United Arab Emirates. (2013) (3)
- Erratum: Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-Analysis of Clinical Trials Leading to FDA Approval (Journal of the National Cancer Institute (2015) 107:11 (djv253) DOI:10.1093/jnci/djv253) (2016) (3)
- Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapy (2014) (3)
- Precision oncology: the intention-to-treat analysis fallacy. (2020) (3)
- Standardized uptake value (SUVmax) in 18F-FDG PET/CT is correlated with the total number of main oncogenic anomalies in cancer patients (2020) (3)
- Imatinib-induced postoperative periorbital purpura: GASP (Gleevec-Associated Surgical Purpura) in a woman with imatinib-treated chronic myelogenous leukemia. (2014) (3)
- Abstract 164: PIK3CA mutation, aspirin use and mortality in patients with metastatic colorectal cancer participating in early-phase clinical trials . (2013) (3)
- Abstract 1279: Loss of PTEN expression in patients treated with PI3K/AKT/mTOR signaling pathway inhibitors (2011) (3)
- DNA in situ hybridization of individual colonies to determine lineage derivation in leukemia (1998) (3)
- Serum Interleukin 6 Levels Are Elevated in Lymphoma Patients and Correlate with Survival in Advanced Hodgkin ' s Disease and with B Symptoms 1 (1993) (3)
- Analysis of CDK12 alterations in a pan‐cancer database (2021) (3)
- Long-Term Safety in a Phase 1 Study of Siltuximab (CNTO 328), an Anti-Interleukin-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease, (2011) (3)
- 1245 POSTER Phase I Dose-escalation Study of the Oral Selective C-Met Inhibitor EMD 1204831 in Patients With Advanced Solid Tumours (2011) (3)
- The checklist: BEST medical center employment requirements 2015. (2015) (3)
- Hematopoietic Growth Factors (2003) (3)
- Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival (2021) (3)
- oligonucleotide in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial. (2018) (3)
- Distinct biological impact of dephosphorylation vs. downregulation of p210Bcr-Abl: Implications for imatinib mesylate response and resistance (2006) (3)
- Cancer: Slaying the 9-headed Hydra. (2022) (3)
- Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act (2017) (3)
- Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis (2023) (3)
- Clinical studies with interferons in Philadelphia positive chronic myelogenous leukemia. (1989) (3)
- Transient severe hyperbilirubinemia after hepatic arterial infusion of oxaliplatin in patients with liver metastases (2013) (3)
- Cytokines in tumor therapy. Interleukin-3. (1991) (3)
- Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response (2022) (3)
- Characterization of cell-free circulating tumor DNA in patients with brain metastases. (2016) (2)
- Targeted therapy for genetic cancer syndromes: Fanconi anemia, medullary thyroid cancer, tuberous sclerosis, and RASopathies. (2015) (2)
- Nuclear factor-K B maintains TRAIL resistance in human pancreatic cancer cells (2006) (2)
- Tumor CTR1 copper transporter modulation by decitabine (DAC) and relationship to global DNA methylation and time from prior therapy (2008) (2)
- Hyperglycemia, hypertriglyceridemia, and hypercholesterolemia in a phase I trial of the combination of an mTOR inhibitor and IGF-1 receptor inhibitor. (2010) (2)
- Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 Therapy (2020) (2)
- Targeting the FGF/FGFR axis and its co-alteration allies (2022) (2)
- Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases (2016) (2)
- P5.01A first in human, dose escalation trial of MSC2363318A – a dual p70S6K/Akt inhibitor, for patients with advanced malignancies (2015) (2)
- Successful implementation of genomically based treatment of chemotherapy refractory peripheral T-cell lymphoma (PTCL) (2018) (2)
- Decitabine effect on human tumor expression of various transporters. (2016) (2)
- The Karabus affair speaks to larger issues for American academic and medical centers. (2013) (2)
- Abstract P3-14-02: Targeting the PI3K/AKT/mTOR pathway for the treatment of mesenchymal triple-negative breast cancer (TNBC): Evidence of efficacy and proof of concept from a phase I trial with dose expansion of mTOR inhibition in combination with liposomal doxorubicin and bevacizumab (2016) (2)
- Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis. (2012) (2)
- Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy (2022) (2)
- BCR Rearrangement-Ne gative C hronic M yelogenous Leukemia R evisited (2001) (2)
- Treatment of acute myelogenous leukemia with chemotherapy and hematopoietic growth factors (1990) (2)
- Survival prolongation by rationale innovative genomics (SPRING): An international WIN consortium phase I study exploring safety and efficacy of avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer (NSCLC) with integrated genomic and transcriptomic correlates (2019) (2)
- 179 Immunotherapy trials lack a biomarker for inclusion: implications for drug development (2020) (2)
- Precision medicine‐based therapies in advanced colorectal cancer: The University of California San Diego Molecular Tumor Board experience (2022) (2)
- Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy (2022) (2)
- Abstract 3418: A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: The salivary gland tumor cohort (2020) (2)
- Advancing the scope of nursing practice: hepatic arterial catheter removal. (2011) (2)
- My personal experiences at the BEST Medical Center: A day in the clinic-the morning. (2016) (2)
- My personal experiences at the BEST Medical Center: A day in the clinic-the afternoon. (2016) (2)
- Abstract B49: GRN1005 phase I studies: Final results. (2011) (2)
- MHC-1 genotype as a predictor of response to immunotherapy. (2019) (2)
- Organic arsenic in patients (pts) with advanced solid tumors: Phase-1 results of zio-101 (s-dimethylarsino-glutathione) (2007) (2)
- Seventeen percent of NGS 50 gene panel variants are not expressed in RNAseq. (2018) (2)
- HIV-positive Kaposi sarcoma and immune checkpoint blockade. (2018) (2)
- Comparison of tissue DNA to circulating tumor DNA in patients with brain metastases. (2017) (2)
- 395 POSTER Phase I study of XL844, a novel Chk1 and Chk2 kinase inhibitor, in combination with gemcitabine in patients with advanced malignancies (2008) (2)
- Molecular dynamics use in personalized cancer medicine: Example of MET Y501C mutation (2016) (2)
- A non-invasive liquid biopsy approach for therapeutic stratification of lung cancer patients. (2015) (2)
- Detection of BRAF mutations in urine and plasma cell-free DNA: Application to the diagnosis and management of histiocytic disorder patients. (2014) (2)
- Phase I trial of sequential azacitidine and valproic acid plus carboplatin in the treatment of patients with advanced malignancies. (2010) (2)
- Circulating tumor and endothelial cells as pharmacodynamic biomarkers in a phase I clinical trial of intravenous bevacizumab in combination with escalating doses of oral cediranib for patients with advanced malignancies. (2016) (2)
- Reply to A. Ocana et al (2010) (2)
- Personalized Cancer Treatment and Patient Stratification Using Massive Parallel Sequencing (MPS) and Other OMICs Data (2018) (2)
- Results of an international phase 2study of the oral farnesyl transferase inhibitor (FTI) tipifarnib (ZARNESTRA®) in patients with high-risk myelodysplastic syndrome (MDS) (2005) (2)
- Identification of putative germline mutations in 10,288 patients undergoing circulating tumor DNA testing. (2017) (2)
- Pharmacodynamics of decitabine 5 days/week x 2 weeks in advanced cancers (2005) (2)
- Novel phase I clinical trials in sarcoma patients: The M. D. Anderson Cancer Center experience. (2010) (2)
- Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer (2016) (2)
- A phase I trial of liposomal doxorubicin (D), bevacizumab (A), and temsirolimus (T) in advanced malignancy. (2009) (2)
- Abstract 2413: Rapid, automated BRAF mutation testing of cell-free DNA from plasma of patients with advanced cancers using the novel Idylla platform (2015) (2)
- 2-Chlorodeoxyadenosine: A new anticancer agent in lymphoid malignancies (1991) (2)
- REPLY to MS#JAAD-D-20-02240: Effective Therapy for Advanced Basal Cell Carcinoma. (2020) (2)
- Abstract B134: PIK3CA mutations in patients with advanced cancers treated in phase I clinical trials (2009) (2)
- Significant Activity of the mTOR Inhibitor Sirolimus and HDAC Inhibitor Vorinostat in Heavily Pretreated Refractory Hodgkin Lymphoma Patients (2013) (2)
- Advanced basal cell cancer: concise review of molecular characteristics and novel targeted and immune therapeutics. (2019) (2)
- Abstract B161: PIK3CA mutations H1047R are associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. (2011) (2)
- BRAF mutation testing with a novel, rapid, fully automated molecular diagnostics prototype platform. (2013) (2)
- 149 INVITED Are there rational novel targets for pancreatic cancer therapeutics? Observations from the M.D. Anderson Cancer Center SPORE in Pancreatic Cancer (2007) (2)
- First-in-human study of AMG 208, an oral MET inhibitor, in adult patients (pts) with advanced solid tumors. (2013) (2)
- Abstract 2410: Cell-free DNA derived from ascites: Detection of copy number and somatic mutations using OncoScan FFPE® Assay (2015) (2)
- Abstract 3417: A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: The small bowel tumor cohort (2020) (2)
- Functional measurement of mitogen-activated protein kinase pathway activation predicts responsiveness of RAS-mutant cancers to MEK inhibitors. (2021) (2)
- Tumor Lysis Syndrome: Introduction of a Cutaneous Variant and a New Classification System (2021) (2)
- NRAS mutations in patients with advanced cancers treated with target-based therapies in early-phase clinical trials. (2012) (2)
- Abstract C120: Genomic landscape in advanced metaplastic breast cancer and outcomes with mTOR targeted therapy. (2013) (2)
- Toxicity in 1,181 patients with advanced solid tumors treated in phase I clinical trials of predominantly targeted agents: The M. D. Anderson Cancer Center experience. (2010) (2)
- Variant allele fraction of genomic alterations in circulating tumor DNA (%ctDNA) correlates with SUVmax in PET scan. (2021) (2)
- Genomic Profiling of Cancers of Unknown Primary Site: The Next Steps. (2015) (2)
- Reply to A. Levy et al. (2013) (2)
- Erratum to: Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases (2016) (2)
- An umbrella protocol for histology-independent, phase I modular study based on EGFR mutation status: Using erlotinib alone or in combination with cetuximab, bortezomib, or dasatinib to overcome resistance. (2011) (2)
- A pilot study of recombinant human interleukin-4 therapy of myelofibrosis. (1999) (2)
- Phase 2 Randomized Discontinuation Trial of XL184 in Patients with Advanced Solid Tumors (2010) (2)
- SPRING: A Worldwide Innovative Network (WIN) Consortium phase I study of triple therapy (avelumab, axitinib, and palbociclib) in advanced non-small cell lung cancer (NSCLC) with genomic and transcriptomic correlates. (2020) (2)
- A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non‐small cell lung cancer (2022) (2)
- Maternal to fetal transmission of cancer: implications for molecular tumor testing, immune regulation, and pediatric malignancies. (2021) (1)
- Abstract 48: Theranostic profiling of adolescents and young adults (AYA) with advanced fibrolamellar hepatocellular carcinoma identifies aberrant activation of the PI3K/AKT/MTOR signaling cascade. (2013) (1)
- A pancancer analysis of impact of MDM2/MDM4 on immune checkpoint blockade (ICB). (2022) (1)
- Personalized medicine in a phase I clinical trials program: The M. D. Anderson Cancer Center Initiative. (2011) (1)
- Hematopoietic Growth Factors and Cytokines (2014) (1)
- The effect of granulocyte-macrophage colony-stimulating factor on undifferentiated and mature acute myelogenous leukemia blast progenitors. (1992) (1)
- Phase I clinical trial outcomes in 93 patients with brain metastases: The M. D. Anderson Cancer Center experience. (2011) (1)
- 18 Pursuing Molecular Stratification in Phase I Trials (2012) (1)
- Dosing Oncology Therapeutics in Combination Therapy for Renal Dysfunction: The University of California San Diego Study of Personalized Cancer Therapy to Determine Response and Toxicity (UCSD-PREDICT) Experience (2018) (1)
- 169 BRAF mutation testing in cell-free DNA from plasma of patients with advanced cancers using a novel, rapid, automated molecular diagnostics prototype platform (Idylla™) (2014) (1)
- A Phase I/II Study of the Oral mTOR Inhibitor RAD001 in Patients with Advanced Hematologic Malignancies. (2004) (1)
- Phase I study of combination vemurafenib, carboplatin, and paclitaxel in patients (pts) with BRAF-mutant advanced cancer. (2015) (1)
- Dual Checkpoint Blockade in a Neuroendocrine Carcinoma With Dual PD-L1/PD-L2 Amplification and High Tumor Mutational Burden. (2020) (1)
- Abstract LB-124: Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors (2012) (1)
- 479 POSTER ZIO-101: a new organic arsenic in advanced cancers (2006) (1)
- Pharmaco-kinetics/dynamics (PK/PD) evaluation and individual patient cross-over studies with growth trajectory assessment to adaptively develop ilorasertib. (2017) (1)
- Inflammation genes and pain severity in lung cancer patients. (2009) (1)
- Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples (2014) (1)
- Analysis of BRAF alterations and molecular profiling in glioblastoma and astrocytoma. (2015) (1)
- Abstract B168: ANG1005: Results of a phase I study in patients with advanced solid tumors and metastatic brain cancer (2009) (1)
- RNAseq in addition to next generation sequencing in advanced genitourinary cancers reveals transcriptomic silencing of DNA mutations: Implications for resistance to targeted therapeutics. (2019) (1)
- Suppressed formation of bone marrow adherent layers derived from acute myeloid leukemia patients after in vitro exposure to interleukin-4. (1997) (1)
- Abstract B194: Phase 1 relative bioavailability study of a prototype oral solution (OS) formulation of the investigational Aurora A kinase (AAK) inhibitor alisertib (MLN8237) in reference to a powder-in-capsule (PIC) formulation in patients with advanced solid tumors. (2011) (1)
- Non-Invasive Monitoring of Urinary KRAS Circulating Tumor DNA for Treatment Response and Minimal Residual Disease in Patients with Lung Adenocarcinoma. (2015) (1)
- Crucial Conceptual Concepts in the Evaluation and Management of Advanced Basal Cell Carcinoma. (2022) (1)
- Comprehensive genomic profiling to identify tumor mutational burden (TMB) as an independent predictor of response to immunotherapy in diverse cancers. (2017) (1)
- Phase I study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancies. (2015) (1)
- Abstract CT053: High rates of personalized molecular matching are achievable in a precision oncology navigation trial: the I-PREDICT study (2017) (1)
- RE: Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials. (2013) (1)
- Significance of scores generated by a cancer therapy matching engine for patient outcomes. (2021) (1)
- Early Phase Cancer Immunotherapy (2017) (1)
- Abstract LB012: Efficacy of atezolizumab in the treatment of solid tumors with high tumor mutational burden (TMB): A MyPathway study cohort (2021) (1)
- Phase I first-in-human study of s-trans, trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors (2008) (1)
- Unilateral proptosis. (2013) (1)
- Survival of 1,181 patients in a phase I clinic: The University of Texas M. D. Anderson Cancer Center experience. (2011) (1)
- 57 – Hematopoietic Growth Factors and Cytokines (2015) (1)
- Analysis of circulating tumor DNA and clinical correlates in patients with esophageal, gastroesophageal junction and gastric adenocarcinoma. (2018) (1)
- ABSTRACTS 32nd Annual Meeting • American Society of Preventive Oncology, Bethesda, Maryland • March 16-18, 2008 (2008) (1)
- Analysis of over 100,000 patients with cancer for CD274 (PD-L1) amplification: Implications for treatment with immune checkpoint blockade. (2018) (1)
- Phase I study of anti-VEGF monoclonal antibody bevacizumab and HDAC inhibitor valproic acid in patients with advanced cancers. (2011) (1)
- IS4. Trials in Progress (2012) (1)
- Abstract CT236: MSC2156119J (EMD 1214063), an oral selective c-Met inhibitor, in patients with advanced solid tumors: results of the first-in-human phase I trial (2014) (1)
- Response to CAR-T Therapy Can be Monitored Using Genome-Wide Sequencing of Cell-Free DNA in Patients with DLBCL (2020) (1)
- Abstract 1287: Profile-related evidence to determine individualized cancer therapy (PREDICT): Preliminary results of the Personalized Phase I Clinical Trials program at MD Anderson Cancer Center (2011) (1)
- 133 POSTER The reproducibility of perfusion parameters obtained from dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) in liver and lung tumors, and implications for sample size in clinical trials using DCE-MRI (2006) (1)
- Stem cell factor (2003) (1)
- Treatment of patients with advanced neurofibromatosis type 2 (NF2) with novel molecularly targeted therapies. (2011) (1)
- BRAF and KRAS mutation testing in plasma cell-free DNA with ICE COLD-PCR in patients with advanced cancers. (2014) (1)
- Abstract 5584: BRAF mutation testing in cell-free DNA from plasma of patients with advanced cancers using a novel, rapid, automated molecular diagnostics prototype platform (IdyllaTM) (2014) (1)
- 450PDFIRST-IN-HUMAN PHASE I TRIAL ASSESSING THE HIGHLY SELECTIVE C-MET INHIBITOR MSC2156119J (EMD 1214063) IN PATIENTS WITH ADVANCED SOLID TUMORS. (2014) (1)
- Expression of p21ras Gene Products in Fresh Primary and Metastatic Human Tumor Tissue (1986) (1)
- JAK: Not Just Another Kinase. (2022) (1)
- Whole exome precision oncology targeting synthetic lethal vulnerabilities across the tumor transcriptome (2020) (1)
- The use of complementary and alternative medicine in patients seen in phase I clinical trials program. (2010) (1)
- Hypoxia-inducible factor-1α (HIF-1α) modulation in combination with anti-angiogenic therapy. (2009) (1)
- HSR19-096: The Impact of New Oncology Drugs on Disability and Health Care Spending: An Assessment of Real-World Evidence (2019) (1)
- Abstract LB-231: Phase Ib dose escalation and biomarker study of MK2206 in combination with standard doses of weekly paclitaxel in patients with locally advanced or metastatic solid tumors with expansion in advanced breast cancer (2012) (1)
- Erratum: Combined modality therapy for cutaneous T-cell lymphoma (Journal of the American Academy of Dermatology (1996) 34 (1022-1029)) (1996) (1)
- Case series of outcomes in advanced cancer patients with single pathway alterations receiving N-of-One therapies (2022) (1)
- Evidence for selective silencing of MHC-binding neoepitopes to avoid immune surveillance. (2019) (1)
- Abstract 2669: Early-phase trials in patients with advanced gallbladder cancer and cholangiocarcinoma: The MD Anderson Clinical Center for Targeted Therapy experience (2012) (1)
- Phase I pharmacokinetic study of dasatinib (BMS-354825) in patients with advanced malignancies and varying levels of liver dysfunction: S0711, a SWOG early therapeutics committee study. (2012) (1)
- Comorbidity between lung cancer and COVID-19 pneumonia: role of immunoregulatory gene transcripts in high ACE2-expressing normal lung (2022) (1)
- Rechallenge with anti-EGFR–based therapy in metastatic colorectal cancer: Impact of intervening time interval and prior anti-EGFR response. (2014) (1)
- Dual inhibition of VEGF pathway: Phase I trial of bevacizumab and cediranib in advanced solid tumors. (2011) (1)
- Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine—Response (2020) (1)
- Dosing immunotherapy combinations: Analysis of 3,526 patients in cancer clinical trials. (2017) (1)
- Abstract 727: Detection of early-stage lung cancer using a liquid biopsy test based on extracellular vesicle proteins (2022) (1)
- Epstein-Barr Virus in Patients with Chronic Lymphocytic Leukemia. (2005) (1)
- Participation and response assessment of older adults with advanced cancer treated on phase I trials as compared to middle age and AYA patients: An analysis of 1489 patients. (2016) (1)
- Abstract A4: Phase I clinical trial evaluating the safety, pharmacokinetics and biological effect of intravenous bevacizumab (avastin) in combination with escalating doses of AZD2171 (cediranib) administered orally for 21 consecutive days to patients with advanced malignancies (NCI protocol #7534) (2009) (1)
- Systematic review of a personalized strategy in cancer clinical trials leading to FDA approval. (2014) (1)
- Cutaneous Metastatic Cancer: Carcinoma Hemorrhagiectoides Presenting as the Shield Sign (2021) (1)
- WINTHER: An international study to select rational therapeutics based on the analysis of matched tumor and normal biopsies in subjects with advanced malignancies. (2017) (1)
- 366 A Phase 1 study of continuous dosing with PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase (2010) (1)
- Assessment of cell apoptosis using radiolabeled EC-TRAIL antibody (2007) (1)
- Abstract 4410: Initiative for Molecular Profile and Advanced Cancer Therapy (IMPACT): A personalized medicine Phase I clinical trials program at MD Anderson Cancer Center: (2011) (1)
- Abstract C203: BRAF and KRAS mutation testing in cell-free DNA and circulating tumor cells from blood of patients with metastatic cancers. (2013) (1)
- Bilateral Postprocedural Rhinitis After Intravenous Sedation With Supplemental Nasal Oxygen (PRAISE SNOG) After Cataract Surgery (2021) (1)
- Siltuximab Treatment Increases Hemoglobin (Hb) Levels: Preliminary Results From a Prospective Phase 1 Study In Refractory Solid Tumors (2010) (1)
- Abstract 5960: Blood-based extracellular vesicle biomarker test for detection of early-stage pancreatic cancer (2022) (1)
- Characteristics and outcomes of patients with gallbladder cancer and cholangiocarcinoma referred to a phase I clinic. (2012) (1)
- Biological response modifiers in the treatment of hematopoietic neoplasia (1992) (1)
- Systematic review of research trends in cancer cachexia: Insights from the literature and funding agencies. (2009) (1)
- Precision oncology: Results of a phase I study of M2698, a p70S6K/AKT targeted agent in patients with advanced cancer and tumor PI3K/AKT/mTOR (PAM) pathway abnormalities. (2018) (1)
- CAT scan reveals BAT sign (2007) (1)
- Thyroid disorders in pregnancy: An overview of literature from Pakistan (2013) (1)
- ENLIGHT: Pancancer response prediction to targeted and immunotherapies via tumor transcriptomics. (2022) (1)
- Abstract 2689: Overcoming BRAF/MEK resistance using vemurafenib with crizotinib or sorafenib in patients with BRAF-mutant advanced cancers: phase I study (2015) (1)
- TCF-001 TRACK (Target Rare Cancer Knowledge): A national patient-centric precision oncology trial for rare cancers. (2021) (1)
- Immunotherapy and Hyperprogression of Disease (2017) (1)
- Abstract B56: A phase 1, open-label, dose escalation, nonrandomized study to assess the maximum tolerated dose, dose limiting toxicity, and pharmacokinetics of OPB-31121 in subjects with advanced solid tumors. (2011) (1)
- 234 POSTER NPI-0052 (a 2nd generation proteasome inhibitor) Phase 1 study in patients with lymphoma and solid tumors (2008) (1)
- Phase I Dose-Escalation Study of Oral Selective C-Met Inhibitor Emd 1214063 in Patients with Advanced Solid Tumors (2012) (1)
- Low dose interleukin-11 is well-tolerated and induces platelet responses in myelodysplasia and other bone marrow failure states (2000) (1)
- Abstract C19: Use of liquid biopsies in clinical oncology: the UCSD Moores Cancer Center experience in 168 patients with diverse malignancies (2015) (1)
- Detection, frequency and actionability of recurrent copy number gains detected by non-invasive liquid biopsy of 3,942 lung and breast cancer samples. (2016) (1)
- Abstract B26: Actionable mutations in cell-free DNA in plasma of patients with advanced cancers referred for experimental targeted therapies. (2013) (1)
- Long-term disease control of ≥2 years achieved with cabozantinib in subjects with metastatic medullary thyroid carcinoma on a phase I study. (2013) (1)
- Prevalence and association of ARID1A with driver alterations and immune checkpoint inhibitor (ICPi) biomarkers in cell-free circulating tumor DNA (ctDNA) from 27,000 non-small cell lung cancer (NSCLC) patients. (2020) (1)
- A phase I study of imexon in combination with docetaxel (DOC) for the treatment of patients with breast, lung and prostate cancer (2008) (1)
- Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in advanced cancers. (2017) (1)
- Expression of p21(ras) in fresh primary human lung tumors (1985) (1)
- PI3K/PTEN/Akt/mTOR pathway aberrations and co-incidence of hormone receptors and HER2 in 19,784 diverse solid tumors. (2015) (1)
- Prevalence of ARID1A Mutations in Cell-Free Circulating Tumor DNA in a Cohort of 71,301 Patients and Association with Driver Co-Alterations (2022) (1)
- PD-L1 gene amplification and focality: relationship with protein expression (2023) (1)
- Predictive value of phase I trials for safety and final approved dose in later trials: Analysis of 33,845 patients. (2013) (1)
- tipifarnib in intermediate- to high-risk myelodysplastic syndrome A multicenter phase 2 study of the farnesyltransferase inhibitor (2012) (1)
- Abstract LB-200: Dose and schedule determination of the Chk1/2 inhibitor LY2606368 in patients with solid tumors. (2013) (1)
- Eliciting early-response signals from first-in-human clinical trials and validation of prognostic scores in aggressive biology bone cancers: The MD Anderson experience. (2014) (1)
- I have good news! You have leukemia. (2007) (1)
- Characteristics and outcomes of patients with advanced hepatocellular carcinoma treated on phase I trials. (2013) (1)
- Targeted therapies in early-phase trials for the treatment of advanced fibrolamellar hepatocellular carcinoma. (2013) (1)
- Abstract 15: Identifying patients with inherited cancer susceptibility through tumor profiling (2014) (1)
- A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors (2015) (1)
- A phase I trial of pazopanib and vorinostat: The role of TP53 mutations. (2014) (0)
- antagonist in chronic myelogenous leukemia: clinical and prognostic Altered levels of interleukin-1 beta and interleukin-1 receptor (2011) (0)
- Abstract 5693: Low coverage genome-wide sequencing of cell-free DNA enables detection, therapeutic monitoring, and characterization of copy number alterations in patients with solid tumors (2017) (0)
- The M. D. Anderson Cancer Center Experience (2009) (0)
- 961P Genomic and transcriptomic profiling in head and neck tumours to identify treatment options: The WINTHER trial experience (2020) (0)
- Genomic analysis of circulating tumor DNA in 442 patients with carcinoma of unknown primary: Implications for targeted therapeutics. (2017) (0)
- Phase 1/2 study of weekly paclitaxel with or without alisertib, an investigational aurora a kinase inhibitor: Phase 1 results in patients with recurrent epithelial ovarian, fallopian tube, primary peritoneal, or breast cancer (2012) (0)
- Next generation predictive biomarkers for immune checkpoint inhibition (2016) (0)
- PD09-01: Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Breast Cancer and PIK3CA Mutations. (2011) (0)
- 1469 A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART SWOG 1609 Cohort 47) in patients with gestational trophoblastic disease (2022) (0)
- Re-visiting EGFR amplification as a target for anti-EGFR therapy: Analysis of cell-free circulating tumor DNA in patients with diverse cancers. (2018) (0)
- Incidence of mucositis in patients treated with mTOR inhibitor-based regimens and correlation to treatment response. (2013) (0)
- Tongue lesions in AIDS (1988) (0)
- Validation of the phase 0 concept. (2011) (0)
- Financial concerns prompt sponsoring pharmaceutical company to halt international phase I studies. (1994) (0)
- Meir Wetzler, MD (2015) (0)
- Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). (2011) (0)
- Clinical outcomes of patients with breast cancer in a phase I clinic: The M. D. Anderson Cancer Center experience. (2009) (0)
- Abstract P1-08-18: PIK/AKT/MTOR pathway activation in triple negative breast cancer and outcomes with matched therapy in phase I clinical trials: Response in both patients with and without direct molecular alterations (2013) (0)
- Abstract CT032: Activity and safety of alectinib for ALK-altered solid tumors from MyPathway (2022) (0)
- Dosing of 3 Targeted Agents in Novel Drug Combinations Used at the Precision Medicine Clinic of the University of California San Diego. (2023) (0)
- Title: Molecular profiling of hepatocellular carcinoma using circulating cell-free DNA Short Title: Cell-free DNA in hepatocellular carcinoma Authors: (2019) (0)
- SWOG S2012: Randomized phase II/III trial of first line platinum/etoposide (P/E) with or without atezolizumab (NSC#783608) in patients (pts) with poorly differentiated extrapulmonary small cell neuroendocrine carcinomas (NEC). (2022) (0)
- Proteins Flexibility as a Criterion for Elucidation of Activating Mutants in Personalized Cancer Medicine (2016) (0)
- L6.5 Personalized Medicine: An Update on 1,985 Patients with Advanced Cancer at Md Anderson Cancer Center (2012) (0)
- Ki-Lymphoma and Interleukin-6 (1998) (0)
- TAS-106 in Combination with Carboplatin is Active in Patients with Refractory Non-Small Cell Lung Cancer And Ovarian Cancer (2012) (0)
- Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial (2019) (0)
- Phase I study of VGX-100, an anti-VEGF-C monoclonal antibody, with or without bevacizumab, in patients (pts) with advanced solid tumors. (2013) (0)
- PI3K/AKT/mTOR genomic alterations in 94 patients with metastatic breast cancer in the phase I clinic at MD Anderson: Prevalence and association with response. (2014) (0)
- Abstract P1-07-15: Detection of molecular alterations in breast cancer through next generation sequencing of both tumor tissue and circulating tumor DNA: The UC San Diego Moores Cancer Center experience (2017) (0)
- Phase I study of and bevacizumab in patients with advanced cancers. (2018) (0)
- RAS alterations: Next-generation sequencing of 1,526 patients with diverse malignancies reveals prognostic and therapeutic correlates. (2018) (0)
- Abstract 43: Clinical implications of real-world data on plasma circulating tumor DNA in gynecologic cancer patients (2020) (0)
- Abstract A95: The determination of the maximum tolerated dose (MTD) of MGCD265 on an intermittent schedule: Phase I study results (Study 265-102). (2011) (0)
- Circulating cell-free DNA molecular profiling among east Asian patients reveals activating MET alterations are common in diverse advanced cancer types. (2018) (0)
- ATM or CHEK2 alterations: Potential biomarkers of improved outcomes with irinotecan-containing chemotherapy in advanced pancreatic ductal adenocarcinoma. (2023) (0)
- Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art (2014) (0)
- Abstract 2298: Understanding tumor biology complexity in the advanced cancer setting: PreciGENE® platform predictions correlate with exceptional responses to cancer treatment (2018) (0)
- Abstract CT201: Phase I study of 5-azacytidine and oxaliplatin in patients with advanced cancers relapsed or refractory to platinum compounds (2014) (0)
- HER2 distribution in diverse tumors: Analysis of 11,493 nonbreast, nongastric cancers. (2014) (0)
- Genomic landscape of diverse rare tumors: Next-generation sequencing of paired DNA and RNA analysis. (2018) (0)
- Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers (2018) (0)
- Retrospective study to elucidate a K-ras phenotype in patients with colorectal cancer. (2011) (0)
- CASE 2. Acquired Hypertrichosis: A Rare Paraneoplastic Syndrome in Various Cancers (2011) (0)
- Of Mice, Not Men: When the Bench-to-Bedside Bridge Is Broken (2022) (0)
- Abstract 1751: A phase I study of lenalidomide in combination with bevacizumab, sorafenib, temsirolimus, or 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in patients with advanced cancers (2012) (0)
- Comprehensive genomic characterization of small cell neuro-endocrine carcinoma of the cervix (2018) (0)
- from Chronic Myelogenous Leukemia Patients Various Subtypes of Philadelphia Chromosome-positive Cells Analysis of P210bcr-abl Tyrosine Protein Kinase Activity in (2013) (0)
- Nailing the Diagnosis: Onychotillomania in Patients With Artificial Nails—An Underrecognized Phenomenon? (2022) (0)
- 1306P Early-stage pancreatic cancer detection using extracellular vesicles (2022) (0)
- Expression of estrogen and progesterone receptors across human malignancies: new therapeutic opportunities (2014) (0)
- Hematopoiesis and the role of growth factors (2003) (0)
- Meeting Unmet Needs With Off-Label Therapies (2020) (0)
- Real-world data from a Molecular Tumor Board: improved outcomes in gynecologic and breast cancer patients with precision medicine (2021) (0)
- Abstract LB-A07: Clinical utility of genomic assessment of blood-derived circulating tumor (ctDNA) in patients with colorectal cancers (2018) (0)
- between protein biomarkers of chemotherapy response and microsatellite tumor mutational burden and PD-L1 expression in cancer patients. (2020) (0)
- Biological molecules in the treatment of hematological disorders. (1989) (0)
- Early-phase trials compared to first- and second-line FDA-approved treatments in patients with advanced gallbladder cancer and cholangiocarcinoma. (2012) (0)
- Comprehensive genomic profiling of circulating cell-free DNA (cfDNA) distinguishes focal amplification (amp) from aneuploidy among MET amps in diverse advanced cancer types. (2019) (0)
- Utility of liquid biopsies to assess circulating tumor DNA in patients with lung adenocarcinoma. (2016) (0)
- Reply to L.D. Locati et al (2012) (0)
- Abstract 1362: Genome-wide sequencing of cell-free DNA enables detection of copy number alterations in cancer patients where tissue biopsy is not feasible (2019) (0)
- Abstract 2303: Decitabine impact on immunohistochemistry scores for tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in human tumor samples (2014) (0)
- Abstract B61: Multicenter phase I clinical trial of an insulin like growth factor (IGF‐R) inhibitor (IMC‐A12) in combination with a mammalian target of rapamycin (mTOR) inhibitor (CCI‐779) to overcome resistance to mTOR inhibition (2009) (0)
- 1521P Comprehensive genomic profiling (CGP) of epithelioid hemangioendothelioma (EHE) and liver angiosarcomas (LAS) (2022) (0)
- Tumor Mutational Burden and PD-L1 Expression in Hematologic Malignancies (2020) (0)
- The role of the electrocardiogram (ECG) in phase I drug development in patients with cancer: The University of Texas M. D. Anderson Cancer Center experience with 8,966 ECGs. (2011) (0)
- Combinations of Genomically and Immune-Targeted Therapies in Early-Phase Clinical Trials (2018) (0)
- Factors influencing a patient's decision to provide a biopsy: Survey of 362 patients in a phase I oncology clinic. (2011) (0)
- Comprehensive Genomic Profiling Reveals Complex and Distinct but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials (2018) (0)
- Turmeric and GreenTea : ARecipe for the Treatment of B-Chronic Lymphocytic Leukemia 55 Commentary on (2009) (0)
- The influence of polymorphisms in cytokine genes on pain and response to analgesia in lung cancer patients receiving palliative treatment (2008) (0)
- ASO Author Reflections: Prognostic Utility of Pre- and Postoperative Circulating Tumor DNA Liquid Biopsies in Patients with Peritoneal Metastases (2020) (0)
- Relationship between protein biomarkers of potential chemotherapy response and microsatellite status in 28,101 cancer patients. (2018) (0)
- Analysis of PllO * " " " " * ' Tyrosine Protein Kinase Activity in Various Subtypes of Philadelphia Chromosome-positive Cells from Chronic Myelogenous Leukemia Patients 1 (2006) (0)
- Fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumab (2022) (0)
- Abstract A202: BRAF mutation testing in cell-free DNA from plasma of patients with advanced cancers using a novel, rapid, automated molecular diagnostics prototype platform. (2013) (0)
- 1246 POSTER A Phase I Dose-escalation Study of EMD 1214063, an Oral Selective C-Met Inhibitor, in Patients With Advanced Solid Tumours (2011) (0)
- Outcomes of patients ≥ 65 yrs with advanced cancer treated on phase I clinical trials. (2013) (0)
- KRAS mutation in endometrial and ovarian cancers: Preliminary data on association with phenotype and clinical outcome in primary disease (2013) (0)
- HER2 expression status in diverse cancers: review of results from 37,992 patients (2015) (0)
- Phase I trial of paclitaxel, bevacizumab, and temsirolimus in advanced solid malignancies. (2016) (0)
- Decitabine impact on the endocytosis regulator RhoA, the folate carriers RFC1 and FOLR1, and the glucose transporter GLUT4 in human tumors (2014) (0)
- Product Data Sheet Chemical Properties Product (2019) (0)
- Reply to J.J.L. Jacobs et al (2009) (0)
- Abstract LB-446: Target-based therapeutic matching in patients with PIK3CA mutations and PTEN aberrations (2012) (0)
- Results from phase 1 dose escalation study of the proteasome inhibitor NPI-0052 in patients with solid tumors and lymphomas (2007) (0)
- Phase Ib study of safety, tolerability, and efficacy of R1507 a monoclonal antibody to IGF-1R in combination with multiple standard chemotherapy regimens in patients with advanced solid malignancies. (2013) (0)
- Genomic landscape of salivary gland tumors. (2015) (0)
- Abstract P5-20-09: Tumor mutational analysis and therapy outcomes for patients (pts) with metastatic/unresectable locally advanced myoepithelial/metaplastic breast cancer treated with PI3K targeted therapy (2012) (0)
- Comprehensive analysis of HER2 status through genomic, transcription, and translation among 5,305 patients with diverse malignancies. (2020) (0)
- Journal of Cancer (2011) (0)
- High tumor amplification burden is associated with TP53 mutations in the pan-cancer setting (2022) (0)
- Abstract 945: Early detection of high-grade IPMN using extracellular vesicles - a successful patient story (2023) (0)
- Unravelling the underpinnings of hyperprogression and immunotherapy: back to the bench (2021) (0)
- Inflammation and cell proliferation signatures: Implications for response to immune checkpoint inhibition therapies. (2020) (0)
- Blood Money: The Cyril Karabus Story (2015) (0)
- Abstract #3606: Azixa, a microtubule formation inhibitor in solid tumors: results of a phase 1 clinical trial (2009) (0)
- Association of VEGF single-nucleotide polymorphisms (SNPs) with response and toxicity in patients treated with bevacizumab. (2011) (0)
- Investigation of profile-related evidence determining individualized cancer therapy (I-PREDICT) in heavily pre-treated patients: A role for combinatorial precision cancer therapy. (2018) (0)
- Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors. (2023) (0)
- Abstract LB-451: Treatment with hormonal blockade in estrogen receptor-positive tumors and correlation with molecular markers: a phase I pilot study of anastrozole in combination with everolimus, bevacizumab, sorafenib or erlotinib (2012) (0)
- Corrigendum (2015) (0)
- c-Met abnormatities in patients with genitourinary (GU) malignancies and outcomes with c-MET inhibitors. (2014) (0)
- Clinical Studies of Alpha and Gamma Interferons in Chronic Myelogenous Leukemia (1988) (0)
- 270 A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the thyroid tumor cohort (2020) (0)
- 914P Early cancer detection using circulating extracellular vesicles (2022) (0)
- 98P An exploration of ARID1A mutations in circulating cell-free DNA (cfDNA) from 68,000 advanced cancer patients: Implications for tumour biology and therapeutic response (2020) (0)
- Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response (2015) (0)
- Fool’s gold, lost treasures, and the randomized clinical trial (2013) (0)
- Germline Testing of Mismatch Repair Genes Is Needed in the Initial Evaluation of Patients With Muir-Torre Syndrome-Associated Cutaneous Sebaceous Neoplasms: A Case Series (2023) (0)
- Computed axial tomography scanning (CT scan). (2006) (0)
- Abstract B123: A phase I study of R1507, a human monoclonal antibody IGF-1R (insulin-like growth factor receptor) antagonist in patients with advanced solid tumors (2009) (0)
- Relationship between tumor mutational burden (TMB) and SUVmax in 18F-FDG PET in cancer patients (2020) (0)
- Myelogenous Leukemia Cells in the Blastic Phase ChronicMyelogenous Leukemia Cell Line ( KBM-5 ) Derived from Mice of a New SCID Biological Properties and Growth in Updated Version (2006) (0)
- 457 Actionable Mutations in Circulating Tumor DNA and Response to Target-based Therapies (2012) (0)
- Abstract 928: Correlation among actionable gene mutations, microsatellite instability and tumor mutational burden in advanced colorectal cancer and association with survival (2023) (0)
- Abstract 6515: Pancreatic ductal adenocarcinoma (PDAC) early detection (2023) (0)
- Letter responds to comment on "intention-to-treat analysis in precision oncology: A cautious interpretation". (2020) (0)
- Clinical outcomes and prognostic factors of hepatic arterial infusion (HAI) chemotherapy combination regimens in 202 patients with advanced cancer metastatic to the liver: The phase I program M. D. Anderson Cancer Center experience. (2010) (0)
- The changing face of phase I protocols: A closer look at study requirements (2007) (0)
- Multiple gene aberrations and breast cancer: lessons from super-responders (2015) (0)
- Abstract CT161: A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the non-epithelial ovarian tumor cohort (2023) (0)
- Studies in target-based treatment (2007) (0)
- Target validation using Phase 0 clinical trials: Promises and pitfalls (2009) (0)
- A phase I study of hepatic arterial infusion of nab-paclitaxel in patients with predominant hepatic metastases. (2010) (0)
- EP991 Exceptional response with combined anti-hormone and MEK inhibitor therapy in a patient with hormone receptor-positive ovarian cancer and isolated KRAS alteration. Implications for a precision medicine strategy (2019) (0)
- Title Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer Permalink (2015) (0)
- Low-dose interleukin-11 has activity in patients with bone marrow failure. (2004) (0)
- Outcomes of pediatric cancer patients enrolled in phase 1 clinical trials designed for adults: Experience from a major cancer center. (2014) (0)
- Contents, Vol. 42, Supplement 1, 1985 (1985) (0)
- Farnesyltransferase inhibitors. (2005) (0)
- 1784P Targeting FGFR signaling with FGFR inhibitor-based regimens: UCSD molecular tumor board experience (2021) (0)
- Carcinoma of unknown primary: Molecular tumor board‐based therapy (2022) (0)
- Biotargets in Sarcomas: The Past, Present, and a Look into the Future (2012) (0)
- Prognostic Significance of Tissue Necrosis Factor-Alpha in Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes. (2007) (0)
- Ecd Literature Search (found with Www.pubmed.gov) Erdheim-chester Disease--clinical Pathological Case Discussion Orphanet Journal of Rare Diseases Erdheim-chester Disease: a Comprehensive Review of the Literature Blood Detection of an Nras Mutation in Erdheim-chester Disease Neurology Teaching Neuro (0)
- growth arrest rather than the rapid and dramatic results that were obtained, given that we were only targeting a single pathway. However, we agree wholeheartedly with the idea of combining both an inhibitor of the PI3K/AKT/mTOR pathway and androgen (2012) (0)
- Abstract B11: Socioeconomic analysis of patients referred for Phase I clinical trials at a dedicated Phase I clinic in a comprehensive cancer center (2009) (0)
- 20P Liquid biopsy of early-stage lung cancer using extracellular vesicles (2022) (0)
- Oncology Research Program. (2017) (0)
- Next-generation sequencing (NGS) in patients with advanced metastatic breast cancer: Identification of molecular alterations and analysis of associations with treatment on phase I studies at MD Anderson Cancer Center. (2013) (0)
- HER2 extracellular domain (ECD) and HER2 single nucleotide polymorphisms (SNPs) in patients treated with combination trastuzumab, lapatinib, and bevacizumab. (2014) (0)
- Immune Escape of AML Cells after Transplantation. (2019) (0)
- Contents Vol. 85, 2013 (2013) (0)
- Genomic Sequencing Reveals Complex and Actionable Molecular Profiles across Hematologic Malignancies (2018) (0)
- A functional measurement of MAPK pathway activation to predict response to MEK inhibitors in RAS-mutated patients. (2019) (0)
- Images in Immunotherapy and Precision Oncology: Angiosarcoma of the Spleen and Liver (2022) (0)
- Abstract 633: Application of a novel analytical metric that quantifies copy number alterations in low-coverage, genome-wide sequencing of cell-free DNA to monitor and differentiate response to immunotherapy in cancer patients (2018) (0)
- Abstract A212: Next generation sequencing (NGS) in 57 patients with advanced or metastatic breast cancer: Identification of unique genomic profiles and correlation with response. (2013) (0)
- Dose-response relationships in phase I trials: Are patients treated at lower doses at a disadvantage? (2009) (0)
- Abstract 2264: K-ras mutations in colorectal cancer may predict a pattern of organ-specific metastasis (2011) (0)
- Phase I Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine Phosphatase Inhibitor, Combined with Interferon Alpha for Pa- tients with Solid Tumors (2007) (0)
- Interleukin-3 (1991) (0)
- Abstract 2771: Clinical outcomes and prognostic factors in 83 patients with pancreatic cancer treated in phase I clinical trials at M.D. Anderson Cancer Center (2010) (0)
- Screening patient-derived tumor cell cultures against a drug library as a promising adjunct to clinical decision-making. (2019) (0)
- Genomic alterations in 670 patients with diverse cancers analyzed by next-generation sequencing (NGS) of circulating tumor DNA (ctDNA). (2017) (0)
- Food Effect Study of the Investigational Aurora a Kinase (AAK) Inhibitor MLN8237 (ALISERTIB) in Patients with Advanced Solid Tumors (2012) (0)
- Granulocyte colony-stimulating factor (1992) (0)
- Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance (2015) (0)
- Perspectives: Bench to Bedside and Back (2008) (0)
- 228 Leukemia inhibitory factor (LIF) stimulates the growth of human breast cancer cells (1995) (0)
- Anti-angiogenic therapy in combination with hypoxia-inducible factor-1α (HIF-1α) modulation (2008) (0)
- 3136 Kinetic monitoring of EGFR and KRAS mutations in urinary circulating tumor DNA predicts radiographic progression and response in patients with metastatic lung adenocarcinoma (2015) (0)
- Survival outcomes of patients who develop new lesions while participating on phase I oncology studies. (2010) (0)
- MHC-I genotype and tumor mutational burden predict response to immunotherapy (2020) (0)
- Abstract 2838: Differential effects of PIK3CA mutations and PTEN loss in patients with advanced endometrial cancers on matched therapy (2014) (0)
- Progression‐free survival 2: Is it ready for prime time? (2022) (0)
- Angiosarcoma heterogeneity and potential therapeutic vulnerability to immune checkpoint blockade: insights from genomic sequencing (2020) (0)
- developmental therapeutics 438 O PHASE II ACTIVITY OF THE HSP 90 INHIBITOR AUY 922 IN PATIENTS WITH ALK-REARRANGED ( ALK + ) OR EGFR-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER ( NSCLC ) (2012) (0)
- liposomal all-trans retinoic acid Alterations in tretinoin pharmacokinetics following administration of (2011) (0)
- 38PMYD88 mutations are associated with a high tumor mutational burden (2016) (0)
- Interim Safety and Toxicity Analysis of a Prospective Phase II Randomized Trial of Checkpoint Blockade Immunotherapy Combined with Stereotactic Body Radiation Therapy in Advanced Metastatic Disease (2018) (0)
- Use of hematopoietic growth factors after chemotherapy (2003) (0)
- Incidence of ERBB gene fusions (EGFR, ERBB2, ERBB4) across tumor types. (2021) (0)
- Successful Treatment of Non-Langerhans Cell Histiocytosis with the MEK Inhibitor Trametinib: A Multicenter Analysis. (2023) (0)
- Abstract B191: Target-matched therapies in patients with advanced cervical cancers harboring PIK3CA mutations and/or PTEN loss. (2013) (0)
- Reply to J.J. Tao et al. (2018) (0)
- A comprehensive genomic analysis of neuroendocrine carcinoma of gynecologic and breast tumors (2018) (0)
- BRAF mutation testing in cell-free DNA from plasma of patients with advanced cancers using a novel, rapid, automated molecular diagnostics platform (Idylla). (2014) (0)
- Abstract 4025: Data-driven computational modeling to identify biomarkers of response to lenvatinib (E7080) in melanoma. (2013) (0)
- Next generation sequencing to reveal potentially actionable alterations in the majority of patients with hematologic malignancies. (2017) (0)
- Pi lot Study of Low-Dose Inter leukin-11 in Pat ients With Bone Marrow Fai lure (2001) (0)
- Genomic profiling and precision medicine in 3,745 patients with advanced cancer. (2014) (0)
- Activity of insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic refractory adrenocortical carcinoma. (2012) (0)
- 66O MyPathway: A multiple target, multiple basket study of targeted treatments in tissue-agnostic cohorts of patients (pts) with advanced solid tumors (2022) (0)
- MEK-inhibitor (inh) and hydroxychloroquine (HCQ) in KRAS-mutated advanced pancreatic ductal adenocarcinoma (PDAC). (2022) (0)
- Abstract C198: BRAF mutation testing of archival tumor samples with a novel, rapid, fully-automated molecular diagnostics prototype platform. (2013) (0)
- Development of extracellular vesicles-based classifier for detection of early-stage bladder, ovarian, and pancreatic cancer. (2021) (0)
- Intra-patient stability of tumor mutational burden from tissue biopsies at different time points in advanced cancers (2021) (0)
- Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications (2015) (0)
- A phase I study of hepatic arterial infusion of oxaliplatin plus intravenous fluorouracil, leucovorin, and bevacizumab in patients with predominant hepatic metastases (2008) (0)
- Abstract 2753: Change in tumor size by RECIST correlates linearly with progression-free and overall survival in phase I studies (2010) (0)
- Pilot S tudy o f L ow-Dose I nterleukin-11 i n P atients W ith Bone M arrow F ailure (2010) (0)
- Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design (2016) (0)
- 992P Pan-cancer T-cell priming transcriptomic markers reveals interpatient immunomic heterogeneity independent of histologic type (2021) (0)
- for the Involvement of Mutated RAS 6 Production in Leukemia : Evidence β Autocrine Interleukin-1 Updated (1999) (0)
- Abstract 5607: BRAF and KRAS mutation testing in plasma cell-free DNA with ICE COLD-PCR in patients with advanced cancers (2014) (0)
- ASO Author Reflections: Circulating Tumor DNA in Peritoneal Carcinomatosis (2018) (0)
- For insights into the real world, consider real-world data (2022) (0)
- The use of dna probes in cancer diagnosis and in monitoring residual disease (1991) (0)
- ERBB family fusions are recurrent and actionable oncogenic targets across cancer types (2023) (0)
- Electronic clinical challenges and images in GI. Image 2. Extensive bilateral extracranial subcutaneous fluid collection. (2009) (0)
- Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer: Genomics Is the Diagnosis. (2023) (0)
- PP65 PIK3CA mutations in patients with advanced cancers treated in a phase I clinic (2009) (0)
- IClinicalTrial of Darinaparsin in Patients with Refractory SolidTumors (2009) (0)
- Abstract 4126: BRAF mutation testing with a novel, rapid, fully-automated molecular diagnostics prototype platform. (2013) (0)
- Abstract B18: PI3K/mTOR pathway aberrations across diverse solid tumors: Analysis of 13,500 patients (2015) (0)
- The master observational trial–a novel method to unify precision oncology data collection. (2020) (0)
- CGE20-070: Gene Silencing: Another Mechanism of Resistance? (2020) (0)
- Association between elevated blood pressure and clinical response in patients treated with anti-vascular endothelial growth factor (anti-VEGF) therapy in phase I clinical trials. (2012) (0)
- The biology of Hepatocellular carcinoma: implications for genomic and immune therapies (2017) (0)
- A rapid method to estimate the value of genetic analysis of excised cancers: A comparison in the phase I setting. (2013) (0)
- Cancer Therapy : Clinical Phase I Study of BIIB 028 , a Selective Heat Shock Protein 90 Inhibitor , in Patients with Refractory Metastatic or Locally Advanced Solid Tumors (2013) (0)
- 1871 Inhibition of mTOR in combination with chemotherapy and angiogenic blockade shows activity in metaplastic breast cancer, an aggressive, chemo-refractory subtype of triple-negative breast cancer (TNBC) (2015) (0)
- Clinical trial design in the era of precision medicine (2022) (0)
- Analysis of the prognostic significance of circulating tumor DNA (ctDNA) in metastatic castrate-resistant prostate cancer (mCRPC). (2020) (0)
- Total number of circulating tumor DNA (ctDNA) genomic alterations and outcome after checkpoint inhibitor-based immunotherapy. (2017) (0)
- Abstract B82: Olanzapine for cachexia in patients with advanced cancer. (2013) (0)
- Abstract CT163: A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the small cell carcinoma of the ovary, hypercalcemic type cohort (2023) (0)
- Biologic Therapy: Hematopoietic Growth Factors, Retinoids, and Monoclonal Antibodies (2005) (0)
- Abstract 1178: Phase I clinical trial of Lenalidomide in combination with Sorafenib in patients with advanced cancer. (2013) (0)
- A phase I study dose escalation clinical study of hepatic intraarterial cisplatin, combination systemic intravenous liposomal doxorubicin in patients advanced cancer dominant liver involvement. (2009) (0)
- FGFR1 and NTRK3 actionable alterations in “Wild-Type” gastrointestinal stromal tumors (2016) (0)
- LAG-3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics. (2023) (0)
- In the era of immune checkpoint inhibitor therapy, can we safely expand to patients with immunodeficiency? (2019) (0)
- Association of CD274 (PD-L1) Copy Number Changes with Immune Checkpoint Inhibitor Clinical Benefit in Non-Squamous Non-Small Cell Lung Cancer (2022) (0)
- Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non–Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies (2022) (0)
- Targeted agents matched with tumor molecular aberrations: Review of 160 patients with advanced melanoma treated in a phase I clinic. (2012) (0)
- Abstract P4-04-15: UC San Diego molecular tumor board: Experience in breast cancer (2013) (0)
- Acknowledgement to the Reviewers (2010) (0)
- Molecular profiling of melanoma tumor biopsies to identify a response signature to the multi-RTK inhibitor, E7080. (2011) (0)
- PD52-12 ANALYSIS OF THE PROGNOSTIC SIGNIFICANCE OF CIRCULATING TUMOR DNA (CTDNA) IN METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC) (2020) (0)
- Pilot study of regional hepatic intra-arterial (HIA) paclitaxel in patients (Pts) with breast carcinoma metastatic to the liver. (2006) (0)
- 765P Comprehensive analysis of the association between RAS mutation and immune checkpoint marker expression (2022) (0)
- Circulating tumor DNA before and after surgical resection in patients with peritoneal carcinomatosis. (2016) (0)
- Biological Properties and Growth in SCID Mice of a New Myelogenous Leukemia Cell Line ( KBM-5 ) Derived from Chronic Myelogenous Leukemia Cells in the Blastic Phase 1 (2006) (0)
- Precision the intention-to-treat analysis fallacy. (2020) (0)
- Effect of decitabine on DNA methylation in human cancers (2006) (0)
- Relationship Between Tumor Mutational Burden and Maximum Standardized Uptake Value in PET (Positron Emission Tomography) Scan in Cancer Patients (2020) (0)
- 105P Dynamic change in blood derived variant allele frequency as a predictive marker for response from checkpoint inhibitor based therapies among metastatic solid tumours (2020) (0)
- A phase 1/2 study of olaparib and radium-223 in men with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases (COMRADE): Results of the phase 1 study. (2021) (0)
- Abstract C69: Phase I trial of lenalidomide and valproic acid in patients with advanced cancer. (2013) (0)
- Abstract IA15: Liquid biopsies: Implications for therapeutic response/resistance and prognosis (2020) (0)
- Efficient clinical research infrastructure and trial performance: Assessment of a dedicated clinical trials unit within an academic cancer center (2016) (0)
- Personalized therapy in diverse cancers: Meta-analysis of 32,149 patients in phase II clinical trials. (2015) (0)
- Therapeutic Interventional Mapping System (TIMS): A novel strategy for the selection of tri-targeted therapy combinations for non-small cell lung cancer (NSCLC). (2015) (0)
- Abstract C149: Next-generation sequencing of biopsy-free circulating tumor DNA revealed frequent actionable alterations in advanced hepatocellular carcinoma (2015) (0)
- Razelle Kurzrock and Shumei Kato on Immunotherapy and Hyperprogression of Disease. (2018) (0)
- Abstract 30: Quantitative monitoring of EGFR mutations in urinary circulating tumor DNA enables non-invasive pharmacodynamic assessment of anti-EGFR drug response (2016) (0)
- Pharmacokinetics, Single-Dose Tolerance, and Biological Activity of Recombinant 7-lnterferon in Cancer Patients1 (2006) (0)
- Abstract 2273: Targeting the PI3K/AKT/mTOR pathway for the treatment of metaplastic breast cancer: Does location of PIK3CA mutation or histology affect response (2016) (0)
- Targeting G1-S phase cell-cycle alterations with CDK4/6 inhibitor-based genomically matched personalized therapy approach. (2020) (0)
- First-in-human phase I dose-escalation study of the oral selective C-met inhibitor EMD 1204831 in patients with advanced solid tumors. (2012) (0)
- Abstract P2-05-03: Anastrozole and everolimus in hormone receptor-positive metastatic breast cancer: Safety profile, activity and associations of molecular alterations in the PI3K/AKT/mTOR pathway (2015) (0)
- Concordance between cancer gene alterations in tumor and circulating tumor DNA correlates with poor survival in a real-world precision-medicine population. (2023) (0)
- Evolution of the Targeted Therapy Landscape for Cholangiocarcinoma: Is Cholangiocarcinoma the ‘NSCLC’ of GI Oncology? (2023) (0)
- Outcome analyses after the first admission to an intensive care unit in patients with cancer enrolled into a phase I clinical trials program: When is the optimal time to trigger code status discussion? (2011) (0)
- Combining Targeted Therapies (2015) (0)
- Cancer immunity marker RNA expression levels across gynecologic cancers: Implications for immunotherapy (2023) (0)
- Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial (2018) (0)
- Abstract 1209: Next generation sequencing demonstrates multiple gene amplifications and mutations in 3 patients with estrogen receptor-positive breast cancer with responses to treatment with combination aromatase and PI3K/AKT/mTOR pathway inhibition. (2013) (0)
- Abstract 1177: Retreatment after secondary resistance: A pilot study. (2013) (0)
- Pre-treatment endogenous interleukin-1 receptor antagonist (IL-1Ra) levels in metastatic colorectal cancer (mCRC) patients are associated with clinical outcomes after anti-interleukin-1a therapy (MABp1). (2017) (0)
- Call to integrate supportive care and patient reported outcomes in early phase clinical trials: An exploration of adolescent and young adult (AYA) participation on phase I trials of novel anticancer agents. (2017) (0)
- Abstract 4387: Molecular profiling for actionable aberrations in advanced osteosarcoma. (2013) (0)
- Abstract 2773: Clinical outcomes of patients with head and neck tumors enrolled in phase I trials is not inferior to outcomes with last treatment line based on an FDA-approved drug (2010) (0)
- EFFECT OF SAMPLING FREQUENCY ON PERFUSION VALUES IN CT PERFUSION OF LUNG TUMORS (2014) (0)
- The Use of Growth Factor Receptor Inhibitors in Human Neoplasms (1994) (0)
- New Rationales and Designs for Clinical Trials in the Era of Precision Medicine (2018) (0)
- Variable mutation expression in human cancers: A 'hide-and-seek' mechanism linked to differential MHC-I presentation dynamics. (2022) (0)
- Hematopoietic growth factors in the transplantation setting (2003) (0)
- Special Report International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease (2019) (0)
- A transcriptomics approach to expand therapeutic options and optimize clinical trials in oncology (2023) (0)
- An 84-Year-Old Woman With an Indolent B-Cell Lymphoma. (2016) (0)
- Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics (2023) (0)
- Post hoc analysis of a long-term safety extension study: Responses to siltuximab in idiopathic multicentric Castleman disease patients receiving on-label dosing. (2022) (0)
- Clinical characterstics and outcomes of patients with BRAF-mutant advanced cancer in a phase I clinic: The University of Texas M. D. Anderson Cancer Center experience. (2011) (0)
- 133P HER2 transcription status of diverse solid tumours with clinical implications (2020) (0)
- Utility of circulating cell-free DNA (cfDNA) analysis in patients with carcinoma of unknown primary (CUP) in identifying alterations with strong evidence for response or resistance to targeted therapy. (2020) (0)
- Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy (2015) (0)
- 31st Annual Meeting • American Society of Preventive Oncology, Houston, Texas • March 2–4, 2007 (2007) (0)
- Characteristics and survival of patients with advanced cancer and TP53 mutations in phase I clinical trials. (2013) (0)
- B-Chronic Lymphocytic Leukemia Turmeric and Green Tea : A Recipe for the Treatment of Updated (2009) (0)
- Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study (2021) (0)
- Targeted Inhibitors: Novel Strategies for Response Optimization. (2015) (0)
- Waun Ki Hong (1942-2019) John Mendelsohn (1936-2019). (2019) (0)
- PARPi post PARPi: Clarity from the Clearity real world experience (164) (2022) (0)
- Cetuximab in Patients with Non-Small Cell Lung Cancer and EGFR Exon 20 Insertion Alterations. (2022) (0)
- leukemia and other hematologic malignancies Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid (2013) (0)
- Serial genome-wide sequencing of cell-free DNA (cfDNA) by assays used in non-invasive prenatal testing (NIPT) to identify copy number alterations (CNAs) associated with immunotherapy response. (2017) (0)
- Biologic Therapy: Interferons, Interleukin-2, and Adoptive Cellular Immunotherapy (2005) (0)
- 253 Screening for PIK3CA, RAS, and RAF mutations in trials with PI3K/AKT/mTOR signaling pathway inhibitors (2010) (0)
- PDL1 landscape in checkpoint inhibitor ineligible patients by IHC and cfRNA. (2019) (0)
- Molecular Medicine in Practice Phase I Clinical Trial of MPC-6827 ( Azixa ) , a Microtubule Destabilizing Agent , in Patients with Advanced Cancer (2010) (0)
- Comprehensive transcriptomic analysis of immune checkpoint markers in a pancancer cohort: Implications for response and resistance. (2022) (0)
- The paradox of cancer genes in non-malignant conditions: implications for precision medicine (2020) (0)
- KI-LYMPHOMA AND INTERLEUKIN-6. AUTHOR'S REPLY (1998) (0)
- 370PDPhase I dose escalation study of M2698, a p70S6K/AKT inhibitor, in patients with advanced cancer (2017) (0)
- Outcome analyses of patients with metastatic cervical cancers in a phase I clinic. (2013) (0)
- Comprehensive Landscape of Cyclin Pathway Gene Alterations and Co-occurrence with FGF/FGFR Aberrations Across Urinary Tract Tumors (2022) (0)
- Dosing de novo two-drug combinations based on 32,894 patients in phase I-III clinical trials. (2016) (0)
- Granulocyte-macrophage colony-stimulating factor (1989) (0)
- Abstract 4928: Relationship between protein biomarkers of potential chemotherapy response and microsatellite status, tumor mutational burden, and PD-L1 expression in patients with cancer (2019) (0)
- Distinct Biological Impact of Dephosphorylation vs Downregulation of p210 Bcr-Abl : Implications for Imatinib Mesylate Response and Resistance. (2004) (0)
- Dermatologic Disease-Directed Targeted Therapy (D3T2): The Application of Biomarker-Based Precision Medicine for the Personalized Treatment of Skin Conditions—Precision Dermatology (2022) (0)
- Hyperprogression in Gastric Cancer: Is MDM2 Amplification the Dark Horse? (2021) (0)
- Poster ViewingAnalysis of Immune Correlates Using Anti-PD-1 Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation Therapy (2017) (0)
- Abstract CT162: A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the clear cell ovarian, endometrial, cervical cancer cohorts (2023) (0)
- Growth factor inhibitory molecules: A novel therapy of leukaemia (1993) (0)
- Genomic-directed personalized matched targeted therapy approach may improve clinical outcomes among patients with advanced pancreatic cancer. (2020) (0)
- Landscape of cyclin pathway genomic alterations across 7,207 non-prostate genitourinary tumors. (2020) (0)
- Topoisomerase expression in solid tumors: Analysis of 24,262 patient specimens. (2015) (0)
- Cyclin pathway genomic alterations across 5,356 prostate cancers. (2020) (0)
- 424 POSTER ANG1005, an Angiopep-2/paclitaxel conjugate: the first clinical trial in patients with advanced cancer and brain metastases: Preliminary safety and tolerability data (2008) (0)
- Molecular biomarkers to predict response to immunotherapy in endometrial cancer patients enrolled on the profile related evidence determining individualized cancer therapy (PREDICT) trial (NCT02478931) at the UC San Diego Moores Cancer Center (2020) (0)
- Abstract B51: A phase I dose‐escalation study of MGCD265 in patients with advanced malignancies (study 265‐102) (2009) (0)
- Genomic analysis of clear cell carcinoma. (2022) (0)
- Anti-angiogenic therapy in combination with hypoxia-inducible factor-1{alpha} (HIF-1{alpha}) modulation (2008) (0)
- Abstract 957: Prediction of patient response to targeted and immunotherapies from the tumor transcriptome in a wide set of indications and clinical trials (2023) (0)
- Macrophage colony-stimulating factor (2003) (0)
- Histological Subtypes of Fresh Primary Human Lung Tumors Differential Expression of p21ras Gene Products among (2013) (0)
- Impact of p 210 Bcr-Abl on Ultraviolet C Wavelength-induced DNA Damage and Repair (2003) (0)
- Granulocyte-macrophage colony-stimulating factor (1994) (0)
- Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies (2015) (0)
- A Phase 1, Open–label Study of Trebananib Combined With Sorafenib or Sunitinib in Patients With Advanced Renal Cell Carcinoma (2016) (0)
- Letter to the editor (2006) (0)
- Using cancer-immunity marker RNA expression levels to compare immunograms across gynecologic cancers (049) (2022) (0)
- Rare tumor clinic: The UCSD Moores Cancer Center experience with a precision therapy approach. (2017) (0)
- Cancer-of-Unknown-Primary-Origin: A SEER–Medicare Study of Patterns of Care and Outcomes among Elderly Patients in Clinical Practice (2022) (0)
- 111 POSTER A dose escalation study of AMG 386, a selective inhibitor of angiopoietin-2, in adult patients with advanced solid tumors (2006) (0)
- Low-coverage, genome-wide sequencing of cell-free DNA developed for noninvasive prenatal testing (NIPT) to enable genomic characterization that can be used to monitor immunotherapy response in cancer patients. (2018) (0)
- Su1015 Transient Severe Hyperbilirubinemia After Hepatic Arterial Infusion of Oxaliplatin in Patients With Liver Metastases (2013) (0)
- Other Hematopoietic Growth Factors (2003) (0)
- Emergence of oral targeted agents in early clinical development: Experience at M. D. Anderson Cancer Center (MDACC) Clinical and Translational Research Center (CTRC). (2010) (0)
- M interleukin-1 ( IL-1 ) receptor antagonist and soluble IL-1 receptors Inhibition of acute myelogenous leukemia blast proliferation (2003) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Razelle Kurzrock?
Razelle Kurzrock is affiliated with the following schools:
- MD Anderson Cancer Center
- University of California, San Diego
- State University of Campinas
- University of Chicago
- University of Vienna
- University of Arkansas
- Autonomous University of Barcelona
- Medical College of Wisconsin
- University of California, Irvine
- University of San Diego
- National Cheng Kung University
- University of Colorado Denver
- Stanford University
- Shanghai Jiao Tong University
